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Abstract 
 
Selective and non-selective nicotinic agonists are associated with improvements in higher order 
cognitive functions. However, the effects of selectively activating nicotinic sub-receptors on 
attention and learning are not well understood. In my project, I used two agonists selective for 
alpha7 (α7) and alpha4-beta2 (α4β2) nicotinic sub-receptors to test the effects of selective nicotinic 
activation on performance in a feature-based reversal learning task in non-human primate subjects. 
Overall, results showed that selective activation of nicotinic receptors led to improvements in 
different aspects of the task which were time and dose dependent: the optimal dose of α7 agonist 
improved performance accuracy and sped up learning of reversals in reward contingency, when 
drug plasma concentration was at its peak. In comparison, the best dose of α4β2 agonist reduced 
susceptibility to distraction. These findings are an important first step to identify the nicotinergic 
neuromodulatory mechanisms of attention and learning functions in the primate brain. 
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Chapter 1-Introduction 
 
1.1 Higher Executive Function 
Higher executive functions are a collection of cognitive processes which enable the organism to 
respond and adapt to environmental changes. Executive functions include but are not limited to, 
working memory, attentional processes, and cognitive flexibility (Robbins, 1996).  Each of these 
functions can be further differentiated into other processes. Working memory is the ability to 
temporarily store a restricted set of relevant information and process them to guide future behavior. 
Working memory is distinct but not independent from other forms of memory. According to the 
Baddeley and Hitch (1974) model, it consists of different components wherein different incoming 
visual, spatial and phonological information are integrated and transferred to long term memory. 
As such, working memory plays an essential role in thinking and decision making.  
Attention describes the selective processing of information. Attention is often studied as a variety 
of processes which can include: 1) the ability to selectively attend to a set of incoming information 
at the expense of other subsets 2) the ability to sustain a selective attentive state over time and 3) 
the ability to shift the attentional allocation from one set of information to another (Bushnell and 
Strupp, 2009). 
 Cognitive flexibility involves adjustable changes in strategies i.e. a set of operations used 
to solve a problem to adapt to unexpected environmental changes (Izquierdo et al. 2016). 
Adjustment to novel situations requires recognition of event changes and directing attention to 
them, inhibition of previously appropriate responses that are not relevant to the new context, and 
devising new strategies that are applicable and goal-directed. 
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 These higher order cognitive processes work in parallel and in coordination with each other 
to optimize decision making for reaching a goal, although the specifics of interaction between 
them is not well understood (Fougnie, 2008). 
 How neuromodulatory systems interact and modulate, i.e. increase or decrease the 
frequency and amplitude of neural activity in brain areas, is important for operation of executive 
functions. Neuromodulatory systems are composed of neurons that can modulate various 
populations of neurons in different brain areas via different groups of neurotransmitters. 
Dopaminergic, noradrenergic and cholinergic neuromodulatory systems, which employ dopamine, 
norepinephrine and acetylcholine neurotransmitters respectively, are suggested to interact and 
modulate visual working memory, selective attention as well as reversal learning (Izquierdo et al., 
2016; Logue & Gould, 2014; Moore & Zirnsak, 2017).  
 For the remainder of this introduction, I will mainly focus on nicotinergic subsystem of the 
cholinergic modulation. I will discuss the putative physiological mechanisms underlying nicotinic 
receptor functions. I will then discuss task paradigms that are commonly implemented in rodents 
and non-human primates to study cognitive flexibility and reversal learning. I will then provide an 
overview of the current literature on specific nicotinic sub-receptors and of the gaps that this thesis 
aimed to fill.   
 
1.2 Cholinergic Modulation of Cognition 
1.2.1 Overview of Acetylcholine 
Acetylcholine (ACh) is a widely-distributed neurotransmitter in both the peripheral nervous 
system (PNS) and central nervous system (CNS). The cholinergic system, which involves 
acetylcholine and the sites affected by it, underlies alertness, cerebral cortical development as well 
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as learning and memory processes in mammalian species (Schliebs & Arendt, 2006). The source 
of cholinergic projections, which are widely sent throughout the brain, originate mainly in the 
basal forebrain, but also from the pedunculopontine and laterodorsal tegmental areas (Picciotto, 
Higley, & Mineur, 2012). The basal forebrain is a collection of multiple subsections including the 
Nucleus basalis of Meynert (NBM) which provides wide projections to the cortex (Gratwicke et 
al., 2013) (Fig. 1). The NBM in rodents is primitive and not well differentiated from the 
surrounding structures while in non-human primates and humans, the NBM has reached its greatest 
development in size and is well differentiated from the surrounding cell types (Mesulam & Geula, 
1988). This species specific difference is possibly due to the massive expansion of the cerebral 
cortex which is the main innervation target of the NBM in primates (Divac, 1975).  
 Post mortem studies have confirmed significant reductions of a particular cholinergic sub-
type receptor (α7 nicotinic receptor) subunit protein in the frontal cortex of schizophrenia patients 
(Guan, Zhang, Blennow, & Nordberg, 1999) and significant loss of the NBM neurons in patients 
diagnosed with Alzheimer disease and Parkinson disease dementia (Etifnne et al., 1986). This 
significant neural loss has been associated with cortical cholinergic deficits and cognitive 
impairments in these patients (Gratwicke et al., 2013). Such evidence is indicative of notable 
contributions of the cholinergic system to learning and memory in humans. In non-human 
primates, local blockade of cholinergic receptors in the perihinal cortex lead to visual recognition 
impairment, possibly due to interference with storage processes of stimulus representation (Tang, 
Mishkin, & Aigner, 1997). Similarly, other local manipulations of the cholinergic system in the 
brain has shown deficits in specific aspects of memory formation in rodents (Hasselmo and Stern, 
2006). The evidence from animal studies suggest that the cholinergic system has a preserved role 
in cognition and memory across different species (Gratwicke et al., 2013).  
  4 
 
 
Figure 1 Proposed cortical and subcortical connections to the NBM for humans. These 
connections are suggested based on anatomical and histological experiments and observations in 
non-human primates, rodents and humans.  The diagram shows different subcomponents of the 
NBM whose relative sizes are scaled with white line divisions. The green and red arrows represent 
afferent and efferent projections respectively. The main cortical areas identified to play role in 
attention set shifting and reversal learning are highlighted in black frames. (Modified from 
Gratwicke et al., 2013). 
            In the PNS, acetylcholine is involved as a neurotransmitter in neuromuscular junction and 
muscle activation. However, in the central nervous system (CNS) it acts as both neurotransmitter 
and neuromodulator, although its means of action are proposed to be predominantly through 
neuromodulation (Picciotto et al., 2012; Rowe & Hermens, 2006). Acetylcholine acts on two main 
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receptor groups (muscarinic and nicotinic) in both nervous systems. Each subsystem consists of 
various sub-receptors that differ from each other in terms of subunit component, local expression 
and pharmacokinetic properties (Dani, 2001).  
 Despite higher expression of muscarinic receptors compared to nicotinic receptors in the 
brain, both subsystems are suggested to be important for attention and learning (Gitelman & 
Prohovnik, 1992). Over the past few decades, clinical evidence consisting of genetic and molecular 
studies supported involvement of nicotinic receptors in some of the observed brain abnormalities 
and associated cognitive impairment in brain diseases such as schizophrenia and Alzheimer’s 
disease. For instance, in-vivo studies have shown nicotinergic interaction with beta-amyloid 
pathologies in animal models of Alzheimer’s disease (Schliebs & Arendt, 2006). Postmortem 
investigation of brain tissues in schizophrenia patients indicated reduction in a nicotinic sub-
receptor expression (Leonard et al., 2000). Given these observations and development of 
pharmacological agents that can selectively agonize/antagonize different nicotinic sub-receptor, 
more neuro-pharmacological studies investigating cognitive modulation through nicotinic 
receptors have been conducted. 
 
1.2.2 Specific Sub-Receptor Effects at the Physiological Level: α7 Versus α4β2 
The nicotinic subsystem, which is composed of ligand-gated ion channels, is classified into a 
variety of receptors. In general, these receptors can be classified into three main functional classes 
based on their pharmacokinetic and physiological characteristics: muscle subunits; standard 
neuronal subunits (α2- α6 and β2- β4), which together form the nicotinic receptors in αβ 
combinations; and subunits (α7- α9) that form homomeric nACh receptors (Dani, 2001). The 
homomeric alpha7 (α7) and heteromeric alpha4 beta2 (α4β2) nicotinic receptors (Fig. 2) are the 
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dominant subtypes expressed in the mammalian brain (Dani, 2001) and of more interest for 
pharmacological interventions. The two sub-types differ from each other in molecular properties 
such as desensitization, affinity and permeability to Ca2+ ions. Receptor desensitization is a 
physiological process where the signaling of the receptor is attenuated in response to high 
concentration levels of the corresponding ligand or agonist. It can regulate receptor affinity (the 
ability of ligand binding to receptors), upregulation and synaptic plasticity (Mansvelder, Keath, & 
McGehee, 2002; Quick & Lester, 2002). Desensitization kinetics interact with activation and in-
activation states of the receptors, although the exact dynamics are still not well-known (Levin, 
2013; Quick & Lester, 2002; Suto & Zacharias, 2004). α7 receptors have comparatively low 
affinity for nicotine and rapid desensitization while α4β2 receptors possess higher affinity for 
nicotine and slower desensitization. Different desensitization kinetics of the nicotinic sub-
receptors are suggested to underlie the rewarding and reinforcing properties of nicotine 
(Mansvelder et al., 2002; Quick & Lester, 2002). Previously it was shown that self-administration 
of nicotine by rats activates the ventral tegmental area (VTA) of the mesolimbic system, an 
important neural pathway for motivation and behavioral reinforcement.  Mansvelder and 
colleagues (2002) showed that upon exposure to low nicotine concentrations, GABAergic 
inhibitory neurons expressing α4β2 nicotinic sub-receptors  in the VTA become insensitive to the 
endogenous cholinergic transmission due to fast desensitization of α4β2 receptors. Thus, their 
inhibitory input to dopaminergic neurons is suppressed and consequently dopaminergic neurons 
are disinhibited. Meanwhile due to slow desensitization of α7 receptors, which are expressed in 
the glutamatergic excitatory neurons, the excitatory transmissions from glutamatergic neurons in 
the VTA is enhanced. If dopaminergic neurons are sufficiently depolarized, their overall 
excitability may be further increased as a result of this glutamatergic transmission. As such, it is 
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proposed that the desensitization kinetics of α4β2 and α7 receptors differentially contribute to 
reinforcing effects of nicotine and its addictive properties.   
 Permeability of receptors to Ca2+ is an important characteristic because this ion is involved 
in cascades of important signaling pathways involved in multiple synaptic plasticity forms such as 
long term potentiation (LTP), paired-pulse facilitation and depression and post-tetanic potentiation 
(PCP) (Citri & Malenka, 2008; Hunter, de Fiebre, Papke, Kem, & Meyer, 1994; Zucker, 1999).  
Nicotinic α7 receptors are highly permeable to Ca2+ ions while α4β2 receptors are much less 
permeable (Albuquerque, Pereira, Alkondon, & Rogers, 2009; Dani, 2001; Quick & Lester, 2002; 
Tanner, Chenoweth, & Tyndale, 2015). In addition, α7 receptors are reported to enhance activities 
of another highly Ca2+ permeable receptor known as N-methyl-D-aspartate (NMDA) receptor 
(Yang et al., 2013). NMDA receptors are glutamate receptors which are also permeable to Ca2+ 
ions and mediate their influx to post synaptic sites. As such, NMDA receptors are involved in 
mediating second messenger pathways important for neural plasticity and memory (Li & Tsien, 
2009).  
 Chen and coleagues (2006) provided evidence for α7 receptor mediation of synaptic 
plasticity in CA1 region of the hippocampus. The authors reported that α7 receptor are necessary 
for LTP induction in the CA1 as blockade of α7 receptors in the Schaffer-collateral inhibited LTP 
induction in naïve rats. Moreover, application of an α7 receptor agonist (GTS-21) restored other 
neural plasticity processes such as PCP which were impaired because of treatment with beta-
amyloid peptides in the same brain area.  
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Figure 2 Two main homomeric and heteromeric nicotinic receptors and their subunit 
arrangements. The binding sites are color coded with different geometrical shapes. As seen in the 
diagram, heteromeric receptors possess different binding sites than homomeric (Zoli, Pistillo, & 
Gotti, 2015). This thesis will only focus on α7 homomeric and α4β2 hetermoeric subtype receptors.  
 
 
 In addition to subunit differences, expression patterns of sub-receptors across brain areas 
and cortical layers can affect modulation of neural activities by these receptors.  In-vitro and in-
vivo experiments have suggested across different cortical layers, pyramidal and interneurons 
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differentially contain α7 and α4β2 receptors in the mouse model. Moreover, neural activities of 
different cell types were also shown to be modulated by nicotinic sub-receptors in a layer 
dependent manner (Arroyo, Bennett, Aziz, Brown, & Hestrin, 2012; Bennett, Arroyo, Berns, & 
Hestrin, 2012; Poorthuis et al., 2013). For instance, in the deep layers of medial PFC (mPFC), 
pyramidal cells were activated by α7 receptors in layer V while in layer VI, the same cell types 
were activated by α4β2 receptors. In contrast, pyramidal cells in layers II/III were not identified to 
be positive for any of the nicotinic sub-receptors. Therefore, it was suggested that excitatory inputs 
to the superficial layers are not regulated by nicotinic sub-receptors (Poorthuis et al., 2013). In the 
studies mentioned above, nicotinic sub-receptor expression in cortical layers was inferred from the 
type of inward currents produced by cell types in response to local application of acetylcholine 
and pharmacological agents antagonizing α7 and α4β2 receptors. In other words, the receptors 
were not directly localized in identified cell types and as such, the reliability of the results is 
debatable.   
 Histological techniques for localization of nACh sub-receptors in both rodents and 
primates are available. However, the current techniques come with limits and hence the obtained 
data must be interpreted with caution (Gotti, Zoli, & Clementi, 2006). For instance, in situ 
hybridization technique is used in localizing the mRNA of receptor subunit, however, expression 
level of protein mRNAs does not necessarily correlate with the expression level of subunits in a 
region. Moreover, techniques such as immunocytochemistry that localize the subunit proteins face 
limitations such as lack of specificity of the antibodies implemented (Gotti, Zoli, & Clementi, 
2006). However, current methods can still be informative of how comparable nACh receptor 
expressions are across different species (Fig. 3). 
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a 
 
b   
 
              
Figure 3 Expression of nACh sub-receptors in different brain areas of rodent (a) and non-human 
primate monkey (b). The distribution mapping of nACh sub-receptors was obtained by localization 
of subunit protein and mRNA techniques in rodent and monkey models respectively (Modified 
from Gotti et al., 2006; Zoli et al., 2015) 
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            Using immunocytochemistry techniques in non-human primates, Disney and colleagues 
(2007) showed that receptors containing *β2 1subunits are mainly expressed in specific subclasses 
of interneurons in the visual cortex (V1). They also found that thalamocortical projections to 
recipient excitatory cells in layer IVc in V1 is mediated via pre-synaptic *β2 sub-receptors. Since 
no available antibodies passed the control experiments in the study, α7 receptors were not localized 
and consequently their contribution to neural responses and information flow could not be 
addressed. Based on these results, it is possible that *β2 sub-receptors modulate feedforward 
processing of information that from thalamus goes to layer IV and from there to cortical output 
layers in the visual cortex (Bloem, Poorthuis, & Mansvelder, 2014; Hasselmo & Sarter, 2011). 
Similarly, excitatory cells in layer V of rodent mPFC were shown to be modulated by *β2 sub-
receptor mediated thalamic projections (Poorthuis et al., 2013). Additionally, the authors showed 
that these excitatory pyramidal cells contained α7 receptors, therefore suggesting response 
modulation of these cells by both sub-receptors. 
 Studies have shown that both systematic and local administration of nicotine is involved in 
bottom-up attentional orienting and can affect spatial attention in response to visual stimuli 
(Noudoost & Moore, 2011). However, how the cholinergic system modulates top-down attentional 
processing and neural activity in non-sensory cortical areas such as the mPFC remains obscure 
(Bloem, Poorthuis, & Mansvelder, 2014; Noudoost & Moore, 2011). To address this, in-vivo 
studies have started to emerge for assessing the effects of endogenously released ACh on task 
performance in behaving animals (Kuchibhotla et al., 2016; Letzkus et al., 2011). For instance, in 
an auditory fear-associated learning paradigm2, Letzkus et al. (2011) identified a neural circuitry 
                                                
1 * β2 receptor refers to a heteromeric receptor with β2 as one of its composing subunits 
2 In fear-associated learning paradigms, animals learn to associate a neutral stimulus (e.g. auditory tone) with an unconditioned 
aversive stimulus (e.g. foot shock) and respond to the tone similar to how they do to the shock i.e. freeze 
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underlying performance in the task which was modulated by the cholinergic system. This circuitry 
involved the layer I interneuron mediated inhibition of particular interneuron sub-classes upon foot 
shocks in the superficial layers (II/III) and disinhibition of excitatory pyramidal cells in the same 
layers. The authors found that similar to foot shocks, photo-stimulation of basal forebrain axons 
alone led to excitation of layer I interneurons. Moreover, local injection of nicotinergic antagonists 
to auditory cortex (A1) during foot shock administration resulted in disinhibition blockade of 
pyramidal cells in layer II/III as well as reduction in freezing (i.e. impaired learning of fear 
association). The sub-receptor specificity involvement in cholinergic modulation of interneuron 
activity was not addressed by the experimenters. Fig. 4 summarizes results about putative nACh 
sub-receptor localization in different cell types across sensory and prefrontal cortex based on the 
studies discussed above.  
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Figure 4 Summary of layer-specific nACh sub-receptor expression across sensory cortices and 
mPFC (Arroyo et al., 2012; Bennett et al., 2012; Disney, Aoki, & Hawken, 2007; Letzkus et al., 
2011; Poorthuis et al., 2013). BF is an abbreviation for basal forebrain. Interneuron subclasses 
include fast and non-fast spiking (FS and NFS) as well late spiking (LS), calbindin and 
somatostatin positive (CB and SOM+). Homomeric receptor refers to receptors with α7 subunit 
while heteromeric to receptors with β2 subunit. Note that layer IV is missing in rodent mPFC and 
the cell types and nAChR expression shown in this diagram is based on a non-human primate study 
(Disney et al., 2007).  
 
 
 
 Neurochemical measurements have provided evidence that cholinergic transients in the 
mPFC during attention control are mediated differentially by α7 and α4β2 sub-receptors. In 
contrast to cholinergic modulation, cholinergic transients consist of fast sub-seconds to seconds 
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ACh release events (Parikh, Ji, Decker, & Sarter, 2010). These transients were released during a 
cue-detection period in a task which required subjects to detect cues predicting reward after a delay 
interval (Parikh, Kozak, Martinez, & Sarter, 2007). On the other hand, the transients were not 
released in trials where cues were missed by animals (rodents). In addition, these transients did not 
occur in another control brain region (motor cortex) (Parikh et al., 2007). The amplitude of 
cholinergic transients was specifically increased by presynaptic α4β2 but not α7 sub-receptors. 
Interestingly, performance of subjects in the task was positively correlated with the amplitude of 
these transients (Parikh et al., 2007). Thus, these results suggest distinct contributions of α4β2 and 
α7 sub-receptors to acetylcholine release in the PFC and attentional control.  
 Aside from regional- and layer-specific expression of sub-receptors, interaction of the 
cholinergic system with other neurotransmitter/neuromodulatory systems adds to the complexity 
of understanding the neural mechanisms underlying executive functions. The cholinergic system 
interacts with dopamine, norepinephrine and serotonergic circuitry (Logue & Gould, 2014). 
Presynaptic nACh sub-receptors are implicated in the release of neurotransmitters such as 
dopamine, norepinephrine, serotonin and glutamate (Duffy, Zhou, Milner, & Pickel, 2009). It is 
suggested that dopamine release mediated by heteromeric sub-receptors in the  mPFC is important 
for attentional set-shifting while nicotinergic release of norepinephrine in the OFC is involved in 
cognitive flexibility such as reversal learning (Logue & Gould, 2014). It is also proposed that 
enhancement of NMDA receptor activity by homomeric nACh sub-receptors (α7)(Fig. 5) is critical 
for persistent network activity in the dlPFC in the absence of sensory stimuli (Yang et al., 2013). 
This finding suggests that α7 receptors play an important role in working memory.  
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Figure 5 Interaction of α7 sub-receptor with NMDA receptors in PFC. (a) The coordination 
between these two receptors as well as muscarinic receptor blockade of potassium channel protein 
are proposed to be involved in rapid changes of cellular networks in the PFC (b) Reversal of 
ketamine –induced performance impairment in DMTS with an α7 sub-receptor agonist (GTS-21) 
in non-human primates. Ketamine is an agent which antagonizes NMDA receptors; Behavioral 
enhancement in these animal provides behavioral evidence for  α7  actions on NMDA receptors 
(Modified from Arnsten, Paspalas, Gamo, Yang, & Wang, 2010). 
 
 Overall, little is known about the mechanisms underlying modulation of top-down 
attentional and higher order cognitive processes by cholinergic subsystems.  How nACh sub-
receptors specifically contribute to these processes depends on many factors such as differential 
expression in cortical and sub-cortical areas, laminar organization, cell type specificity and 
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interaction and coordination with other neurochemical networks. Additional research is required 
to shed light on neural mechanisms underlying cholinergic regulation of executive function.   
1.3 Studying Nicotinergic Mediation of Higher Executive Functions 
Previous studies trying to elucidate nicotinergic modulation used various task paradigms. These 
paradigms have specific strengths but also limitations. The most commonly used tasks in 
nicotinergic studies will be described and discussed in the following sections. 
1.3.1 Delayed Match to Sample Task  
This task is developed in different versions to study working memory and is mainly implemented 
in non-human primate studies. As shown in Fig. 6, a single stimulus (cue) is displayed on a screen. 
After a retention time interval (delay period), the subject is required to make a response by finding 
the match to the original cue. The stimuli and retention time intervals used in the task vary from 
trial to trial (Rodriguez and Paule, 2009). In some studies, distracting stimuli are sequentially 
displayed in the retention interval. Such manipulation allows for increasing the difficulty of the 
task. More importantly, it makes the task more comparable to real-world case scenarios where 
memory is retained after storing and processing new information (Miller, Li, & Desimone, 1993).   
Age-dependent cognitive deficits have been observed in monkeys performing DMTS. Thus, 
implementing this task with aged monkeys can be used to study Alzheimer’s disease. Introduction 
of distractors during retention intervals also allows for evaluating sustained attention and making 
the task relevant for studying attention deficit disorders. DMTS tasks also demonstrate sensitivity 
to pharmacological testing. A summary of studies that investigated the effects of selective 
cholinergic pharmacological agents in DMTS tasks will be discussed in later sections.  
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Figure 6 Delayed match to sample task (a) A schema of the task version without any intervening 
stimuli during retention intervals. Longer time intervals tend to cause greater impairment in 
performance. (b) A schema of the task version where variable number of distractors are introduced 
to increase the attention load and intricate the working memory-dependent performance.   
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1.3.2 5-Choice Serial Reaction Time Task 
The 5- choice serial reaction time task (5-CSRTT) originally developed by Robbins et al. (1983) 
is used for studying sustained attention, mainly in rodents. This paradigm has been used in various 
studies investigating the nicotinergic effects on sustained attention (Hahn, Sharples, Wonnacott, 
Shoaib, & Stolerman, 2003; Hahn, Shoaib, & Stolerman, 2011; Hoyle, Genn, Fernandes, & 
Stolerman, 2006; Kolisnyk, Al-onaizi, Prado, & Prado, 2015; Young et al., 2004). Table 1 
summarizes the behavioral effects of a number of nicotinergic studies employing this task. 
Essentially, these tasks measure how well subjects can maintain their attentiveness to detecting a 
stimulus presented in different spatial locations. Typically, the animal is placed in an apparatus 
with 5 panels and a food magazine where reward can be obtained (Fig. 7). In each trial, brief 
flashes of light (cue) are presented in one of the panels in a pseudorandom sequence. The subject 
is required to detect the light in the right spatial location and respond to it by nose poking to the 
panel. The difficulty of the task is manipulated via duration and brightness of the light stimuli 
presented in a panel; shorter duration and less brightness increase the load on sustained attention 
and therefore lead to decreased performance. Another variant of this task is the 3-choice serial 
reaction time task (3-CSRTT) developed by Bunsey et al. (1995). Most nicotinergic studies use 
the 5-CSRTT in their experiments. To the best of my knowledge, only Tsutsui-Kimura et al. (2010) 
used this variant to assess the cognitive effects of two nicotinic sub-receptor drugs. This variant is 
very similar to the first, except for there are 3 panels in the apparatus and the food magazine is 
located differently, under the central point of the response port. The latter characteristic of 3-
CSRTT is proposed to prevent the distracting effect of turning around and obtaining reward from 
the back of the apparatus. In both task variants, distracting stimuli (usually olfactory or auditory) 
can be introduced to assess selective attention. (Accornero et al., 2009; Bunsey & Strupp, 1995; 
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Moon et al., 2006). The distracting stimuli are usually presented after the trial onset and before 
cue presentation at the panels (Bushnell and Strupp, 2009). In general, five indices of behavioral 
measurement are reported with this task: 1) Correct response rate: the percentages of correct to 
total choices, 2) Omission rate: the percentage of non-initiated trials (omissions) by total trials in 
the task. 3) Pre-mature responses: number of responses made during the inter-trial periods, 4) 
Correct latency, defined as the time it took the subject to respond to the cue in the correct panel 
and 5) Magazine latency which is the time it took the subject to retrieve food at the magazine after 
nose poking at the correct panel (Robbins, 2002). Since its development, 5-CSRTT has been used 
in numerous experiments to study attentional dysfunction in disease models and effects of 
pharmacological interventions (Buschnell and Strupp, 2009). However, limitations imposed by 
behavioral measurements in this task can obscure the results of pharmacological studies. Correct 
and magazine latencies are sensitive to changes in locomotor activities and thus the effects 
observed in the task may not be due to cognitive-related aspects of a drug. In addition, pre-mature 
responses which are used as measures of impulsivity (i.e. actions without forethought) can be 
sensitive to pharmacological-induced variations in motor functions. Similarly, changes in omission 
rates may be due to non-cognitive effects of drugs and not increased distractibility per se. It has 
been shown that selective and non-selective nicotinic agonists can increase locomotor activities in 
rodents (Grottick et al., 2000; Reavill, CStolerman, 1990). Therefore, dissociation of cognitive 
from locomotive effects are of great importance when studying the effects of nicotinergic drugs in 
behavioral tasks. 
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Figure 7 5 Choice serial reaction time paradigm for rodents. Common apparatus used for the task 
includes five spatial locations and a food magazine. In this example, light is illuminated in the 
second panel from right (Modified from Robbins, 2002). 
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1.3.3 Sustained Attention Task  
As discussed above, it can be hard to disambiguate the attentional effects of independent variables 
such as pharmacological intervention from non-attentional processes in 5-CSRTT task. To provide 
better measurements for estimating response rates and false alarms (incorrect responses in the 
absence of stimuli/cue), newer versions of the sustained attention task were developed. These tasks 
first introduced by McGaughy and Sarter (1995) and collectively termed as sustained attention 
task (SAT) (Fig. 8), differ from 5-CSRTT tasks in few ways. First, the spatial aspect of the 5-
CSRTT is removed as the cue (light stimulus) is presented only in one existing panel in the 
apparatus, however, the temporal aspect including timing of the trial onset and stimulus duration 
is maintained. Second and more importantly, discriminatory operations are involved. Once the cue 
is displayed, the subject is presented with two extendable levers to respond to the presence or 
absence of a light cue. As such, experimenters are enabled to dissociate between hits (correct 
responses to the presence of a stimulus), misses (lack of responses), false responses and correct 
rejections (correct response to the lack of a stimulus). Third, the levers are not available before cue 
presentation, thus, unlike 5-CSRTT, subjects cannot respond during inter-trial intervals. 
 To manipulate task difficulty, stimulus duration and inter-trial intervals can be varied. In 
addition, distracting stimuli can be introduced during inter-trial intervals. Presenting light flashes 
as distractors have shown to result in performance decrement over time (Howe et al., 2010).  
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Figure 8 A visual signal detection task used to assess sustained attention in rodents. Signal levers 
are used by subjects to respond to signal trials, where light cue was illuminated and blank levers 
are used to respond to blank trials, where light cue was absent. Similar to 5-CSRTT, variable 
interval timings (VI) were considered prior to and post signal (light illumination) presentation. 
(Modified from Rezvani et al., 2009). 
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1.3.4 Intra/Extra-Dimensional Set Shift Task  
Intra/Extra-Dimensional Set Shift Task (ID/ED) is another task for evaluating executive functions 
which assesses and distinguishes between two different aspects of cognitive processes:  1) 
flexibility in regard to reversal of discrimination learning and 2) flexibility in regard to shifting 
attention from one perceptual dimension to another (Izquierdo et al., 2016). Essentially, the task 
consists of multiple stages which can be arranged in different numbers across task variants. The 
first stage starts with a simple discrimination wherein two exemplars (stimuli) differing in one 
feature (e.g. odor) are presented. The subject then needs to learn which exemplar is rewarded based 
on the dissimilar feature (i.e. odor). In the next stage, the subject learns a compound discrimination.  
The difference from the previous stage lies in the two exemplars differing from each other in both 
features (i.e. odor and texture). It should be kept in mind that the same feature that was rewarded 
in the first stage is still rewarded in this phase. This is followed by the first reversal event in the 
task i.e. reward contingencies switch such that the previously un-rewarded odor becomes rewarded 
for the first time. Subsequently, the subject is faced with a new set of exemplars. Both features are 
different but, similar to simple and compound discriminations, odor still determines which 
exemplar is rewarded. This is the intra-dimensional shift stage of the task which is followed by a 
second reversal. Next, the other feature which was not rewarded in the previous steps (i.e. texture) 
is rewarded and odor is not to be reinforced again. Finally, a third reversal in respect to texture 
takes place and the task ends.  
 ID/ED set shifting tasks have been implemented in both rodents and non-human primates. 
Fig. 9 and 10 show a task example developed for each species. Conceptually, the tasks are similar 
between the animal models, however, there are few differences between them. The performance 
criterion for rodents is usually set to 6 consecutive trials and for non-human primates is set to 18/20 
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correct trials. Additionally, while rodents complete only one reversal at each stage, non-human 
primates perform serial reversals (Izquierdo et al., 2016). To the best of my knowledge, no non-
human primate studies have used set shifting task to evaluate the effects of α4β2 and α7 nicotinic 
receptors. Therefore, the rest of this section will focus on ID/ED set shifting task in rodents.  
 For both species, the ED shift stage of the task is the most difficult of all phases and subjects 
require a higher number of trials to reach the criterion. Both species may complete all stages of the 
task within one session or across multiple sessions (Izquierdo et al., 2016). In rodents, the task 
variant that takes place all in one session is known as the “sand-digging” (Fig. 9) and originally 
developed by Birrell and Brown (2000). Given the time and technical efficiency, this variant is 
usually preferred to the “operant” task (Bushnell and Strupp, 2009) which is carried out across 
multiple sessions inside expensive operant chambers (Scheggia & Papaleo, 2016). However, there 
are limits with the sand-digging variant. First, unlike the operant-based task which is automated, 
sand-digging is carried out manually and the experimenter should present the trials and change 
exemplars by hand. This can also increase subjectivity-based biases in the measured parameters. 
Second, involving food related reinforcers in the exemplars can lead to possible choice biases by 
the subjects (Gilmour et al., 2013). Third, across multiple lesion and pharmacological studies 
(some examples provided in Table 1), only the ED shift stage was shown to be affected by the 
experimental manipulations (Bushnell and Strupp, 2009). The reason for this phenomenon may be 
related to the duration of this stage which varies between the two task variants. In the operant 
version, the ED shift stage is performed by subjects for a more prolonged time, and allows for 
evaluation of behavior during multiple phases: perseverative, chance and post-chance. These 
phases may allow studying perseverative responses to the previously rewarded exemplar, trial and 
error efforts, and a steadier learning of the new reward contingencies respectively. Therefore, 
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deficits in different attentional processes such as attention shift (i.e. problem of shifting from the 
previously rewarded exemplar, reflected in perseverative phase) and selective attention (i.e. 
problem of filtering out previously rewarded exemplar, reflected in post-chance phase) can be 
distinguished from each other (Scheggia & Papaleo, 2016). Despite these advantages, the operant-
based task is not a very optimal design for pharmacological studies in which the temporal 
administration of drugs is an important variable. In other words, how performance in each stage 
can be affected by pharmacological manipulations can vary depending on when drugs are 
administered. For instance, drug administration before any reversal can affect acquisition (i.e. 
discrimination between stimuli) while after reversal can affect other learning processes (Gilmour 
et al., 2013).  
 Other paradigms have also been designed for evaluating reversal learning. Such tasks 
usually involve spatial discriminations (Redrobe et al., 2009; Terry, Plagenhoef, & Callahan, 2016; 
Thomsen, Christensen, Hansen, Redrobe, & Mikkelsen, 2009). The major limitation in these tasks 
is that reversals are done based on spatial locations and can involve employment of spatial 
strategies by subjects.  
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Figure 9 A sand-digging version of ID/ED shift task developed by Brown (2005). Prior to training 
for multiple stages of the task, subjects are trained to dig for the hidden food inside the bowls. The 
features enclosed by black rectangles are rewarded. Green checkmark indicates which compound 
stimulus is rewarded at each stage. 
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Figure 10 An ID/ED set shifting task implemented with marmoset monkeys. Although not shown, 
serial reversals follow the first reversal in this task (Roberts et al., 1994).  
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1.4 Nicotinic Sub-Receptor Effects at Behavioral Level: α7 Versus α4β2 
Results from behavioral experiments investigating the specific contribution of nicotinic sub-
receptors to learning and attention have not been very consistent. Depending on the agonist, 
selected doses and behavioral paradigms, different and sometimes seemingly contradicting effects 
of nAChRs on cognitive task have been reported. Table 1 demonstrates a summary of rodent 
literature that has investigated the effects of α7 and α4β2 sub-receptor agonists on attention and 
ID/ED tasks. 
 Multiple studies showed cognitively enhancing effects of α7 sub-receptors in schizophrenia 
animal models measuring sensory gating (Hauser et al., 2009; O’Neill, Rieger, Kem, & Stevens, 
2003; Wishka et al., 2006). Sensory gating is the ability to filter out irrelevant and unnecessary 
information in the environment and it is documented as one of the hallmarks of cognitive deficits 
in schizophrenia (Baker et al., 1987). However, auditory sensory gating per se is primarily not a 
measure of attention or learning.  Other measurements such as response accuracy and omission 
errors in task constructs such as 5 CSRRT in rodents have shown potential involvement of both 
sub-receptors in mediating pro-cognitive effects. For instance, studies with both wild type and α7 
knock-out (KO) models reported reduced level of omission errors by these sub-receptors (Hahn et 
al., 2011; Hoyle et al., 2006; Young et al., 2007; Young et al., 2004). Another pharmacological 
study also reported enhancing effects of α7 sub-receptor agonist in a SAT task where percentage 
of hits were increased (Rezvani et al., 2009). However, the literature is not void of inconsistencies: 
Kolisnyk (2015) and colleagues showed that while KO models of mice showed behavioral 
deficiency in 5-CSRTT task, they failed to show any significant improvement when systematically 
injected with two different  α7 agonists. Interestingly, an α2β2 agonist ameliorated performance 
in the α7 KO subjects. Contrary to these results, the authors found improved performance in wild 
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type mice when injected with low doses of α7 agonists. In another study, α7 KO animals did not 
show any performance impairment compared to wild type while *β2 KO subjects experienced 
increase in omission errors. Additionally, re-expression of the receptors with *β2 subunits in the 
PFC reduced omission errors and resulted in a performance comparable to that of wild type mice 
(Guillem et al., 2011). Concordantly, Howe ( 2010) did not observe any significant behavioral 
changes as a result of α7 agonist administration in mice performing SAT and SAT-d tasks but they 
reported increases in percentage of hits with α4β2 agonist in SAT-d task only. Consistent with 
these findings, (Paolone, Angelakos, Meyer, Robinson, & Sarter, 2013) demonstrated differential 
ACh release in the PFC of two groups of rodents performing a SAT task. They found a higher 
level of ACh release in rodents employing optimal learning strategies compared to those utilizing 
poor strategies. Interestingly, the α4β2 agonist used in this study led to acetylcholine augmentation 
in the PFC of poor learners only. Literature on sub-receptor mediation of reversal learning is 
scarce. There are few studies on nicotinic sub-receptor effects on performance in attention set 
shifting tasks (Jones et al., 2014; McLean et al., 2012; Wallace & Porter, 2011). It was found that 
an α7 agonist restored performance in subjects experiencing phencyclidine-induced impairment in 
extra-dimensional switch such that subjects required fewer trials to reach the criterion (Wallace et 
al., 2011). Similarly, three different α7 agonists also resulted in enhanced improvement in ED shift 
(Jones et al., 2014), however, in comparison with Wallace et al. (2011) and McLean et al. (2012), 
there were two task-related differences: 1) the subjects were not tested in one session but over two 
days 2) reversal learning was not evaluated and only performance in ED shift was investigated. 
Both studies tested the effects of the agonists in animal models which were behaviorally impaired 
with NMDA receptor antagonizing agents. These results are consistent with the findings of Allison 
& Shoaib (2013) where the authors showed nicotinic–induced enhancement of performance in 
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healthy rodents during ED- shift stage of the task only. However, due to using nicotine (the general 
agonist), specific contributions of sub-receptors were not addressed in this study. To the 
knowledge of the author of this thesis, no studies have been conducted to test the effects of α4β2 
sub-receptors on performance in set-shifting tasks.  
 There are different possibilities for the observed discrepancies across the literature: KO 
models can be limited in result interpretation given that these animals may develop different 
compensatory systems that otherwise would not exist in the wild type (Bloem et al., 2014). In fact, 
deletion of *β2 sub-receptors in mice can result in upregulation of muscarinic receptors in layer 
VI of the mPFC. This layer in healthy animals shows dominant expression of nicotinic sub-
receptors wherein excitatory pyramidal cells are modulated by *β2 sub-receptors (Kassam, 
Herman, Goodfellow, Alves, & Lambe, 2008; Poorthuis et al., 2013; Tian, Bailey, De Biasi, 
Picciotto, & Lambe, 2011). Poor CNS penetration in agonists utilized in earlier studies and 
selection of doses higher than the optimal level were also suggested to be a possible reason for 
inconsistent results (Hahn et al., 2011; Tanner et al., 2015). Finally, task designs and measuring 
indices of behavior can also change results and interpretations.  
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Table 1 Effects of selective nicotinic sub-receptors on learning and attention in rodents across different studies. 1 Agonists 
selective for α7 nAChRs. 2 Agonists selective for α4β2 nAChRS. Doses that led to behavioral improvement are highlighted in bold 
font. 
Pharmacological 
Agent  
Task Attention Control Response Mapping Doses 
Tested 
References  
SSR-1807111 ID/ED set shifting Select newly rewarded 
exemplar over the previous one 
Digging in the bowl 
containing the rewarded 
feature 
1,3 and 103 
mg/kg 
(Jones et al., 2014) 
RG-34871 ID/ED set shifting 
 
 
 
SAT 
Select newly rewarded 
exemplar over the previous one 
 
- 
Digging in the bowl 
containing the rewarded 
feature 
 
Press lever corresponding to 
presence or absence of a 
stimulus 
 
0.03, 0.1, 0.3 
and 1 mg/kg 
 
 
0.6 mg/kg 
(Wallace et al., 2014) 
 
(Rezvani et al., 2009) 
 
GTS-211 ID/ED set shifting Select newly rewarded 
exemplar over the previous one 
Digging in the bowl 
containing the rewarded 
feature 
3,10 and 30 
mg/kg 
(Jones et al., 2014) 
PNU-282,987 ID/ED set shifting Select newly rewarded 
exemplar over the previous one 
Digging in the bowl 
containing the rewarded 
feature 
3, 10 and 30 
mg/kg 
 
 (Jones et al., 2014) 
 
 
PNU-120596  ID/ED set shifting Select newly rewarded 
exemplar over the previous one 
Digging in the bowl 
containing the rewarded 
feature 
10 mg/kg Mclean, 2012 
AR-R17779  5-CSRTT - Nose-poke to the location of 
detected object 
3,6,12 and 24 
mg/kg 
(Hahn et al., 2003) 
PHA-5436131 5 CSRTT - Nose-poke to the location of 
detected object 
0.33, 1 and 3 
mg/kg  
(Kolisnyk et al., 2015) 
PNU-282,9871 5-CSRTT - Nose-poke to the location of 
detected object 
1,3 and 5 
mg/kg 
(Kolisnyk et al., 2015) 
ABT-4182 5 CSRTT 
 
 
 
- Nose-poke to the location of 
detected object 
0.04, 0.13 
and 0.39  
0.05, 0.1, 0.2 
and 0.4 
mg/kg 
(Kolisnyk et al., 2015) 
 
 
(Hahn et al., 2003) 
ABT-0892 SAT - Press lever corresponding to 
presence or absence of a 
stimulus 
0.02 and 0.1 
mg/kg 
(Paolone et al.,  2013) 
S-382322 SAT 
 
 
 
 
dSAT4 
- 
 
 
 
 
Respond to presence or absence 
of light cue while ignoring a 
flashing light distractor 
Press lever corresponding to 
presence or absence of a light 
cue 
 
 
Press lever corresponding to 
presence or absence of a light 
cue 
0.03, 0.30, 
1.00, and 
3.00  
0.03, 0.30, 
1.00, and 
3.00  
 
(Howe et al., 2010) 
                                                
3 Effective doses are highlighted in bold font 
4 dSAT refers to a variant of SAT tasks that implement distractors.  
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 In non-human primate models, multiple studies using the DMTS task have provided 
evidence for enhancing effects of both sub-receptors on working memory (Table 2). Evidence for 
selective attention modulation by nicotinergic sub-receptors comes from studies that implemented 
distractor in DMTS task (Buccafusco, Terry, Decker, & Gopalakrishnan, 2007; Prendergast et al., 
1998). It should be noted that neither study has compared the effects of α7 to α4β2 sub-receptors 
and reported results for α4β2 agonists only. Insufficient number of studies on reversal learning are 
conducted in non-human primates. These studies were different in task design and measured 
indices of performance. Terry et al. (2016) carried out the reversal in ketamine-impaired subjects 
over 24-48 hours and only reported proportion of correct choices and error types such as 
perseverative tendencies but did not report trials to reach the criterion (i.e. learning rate). The main 
effects included higher proportion of correct responses under drug condition and attenuation of 
perseverative errors. Gould et al. (2013) conducted two reversals with different sets of exemplars 
(i.e. no serial reversals) and did not find effects on any behavioral components in either cocaine-
impaired or healthy subjects. Neither study addressed possible differential sub-receptor 
modulation as they utilized agonists selective for both receptor types (Terry et al., 2016) or only 
agonists selective for α7 but not α4β2 sub-receptor. In summary, more experiments in non-human 
primates are needed to clarify the effects of the nicotinic sub-receptors on filtering distraction and 
reversal learning. 
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Table 2 Effects of selective nicotinic sub-receptors on learning and memory in non-human primates across different studies. 1 
Agonists selective for α7 nAChRs. 2 Agonists selective for α4β2 nAChRS. 3 Agonists selective for both α7 and α4β2 nAChRs.  
Doses that led to behavioral improvement are highlighted in bold font. 
Pharmacological Agent  Task Attention Control Doses Tested References  
GTS-211 
 
DMTS 
 
 
- 3, 6.2, 12.4, 24.8 
5and 49.6 µg/kg 
 
2.5,5,10,20,40 
µg/kg  
(Briggs et al., 1997) 
 
 
 
(Buccafusco & 
Terry, 2010) 
PNU-282-9871 
 
DMTS 
 
 
Reversal learning 
- 
 
 
Select newly rewarded object over the 
previous one 
0.0016-0.56 µg/kg  
0.001-0.56 µg/kg  
(Gould et al., 2013) 
(Gould et al., 2013) 
 
A-5829411  DMTS - 1.4,11,4 and 38 
µg/kg  
(Buccafusco et al., 
2007) 
PHA-5346131 Spatial 
working memory  
 
- 0.01, 0.1, 1, 10 
µg/kg  
(Yang et al., 2013) 
 
ABT-4182 DMTS-D7 
 
 
 
DMTS 
Visual distraction during delay (25% of 
trials) 
 
 
- 
0.41, 0.82, 1.64, and 
3.28 µg/kg  
0.41, 0.82, 1.64, and 
3.28 µg/kg  
0.41, 0.83, 1.64, 
3.28, 6.57 µg/kg 
(Prendergast et al., 
1998) 
 
 
(Prendergast et al., 
1998) 
 
(Buccafusco et al., 
1995) 
ABT-0892 DMTS-D 
 
 
DMTS 
Visual distraction during delay (25% of 
trials) 
 
- 
1.1, 2.2, 4.4, 8.8, 
and 17.7 µg/kg  
1.1, 2.2, 4.4, 8.8, 
and 35.2 µg/kg  
(Prendergast et al., 
1998) 
 
(Decker et al., 1997) 
ABT-5942 DMTS-D 
 
 
 
 
DMTS 
Visual distraction during delay (25% of 
trials) 
 
 
 
- 
0.115-3.7 µg/kg 
 
0.115-3.7 µg/kg 
(Buccafusco et al., 
2007) 
 
 
 
 
Varenicline3 
 
DMTS 
 
DMTS 
 
Reversal learning 
- 
Visual distraction during delay (25% of 
trials) 
 
Select newly rewarded object over the 
previous one 
0.03, 1, 3.0 mg/kg  
 
0.03, 1 ,3.0 mg/kg  
0.03, 1 ,3.0 mg/kg  
(Terry et al., 2016) 
 
 
(Terry et al., 2016) 
                                                
5 Effective doses are highlighted in bold font 
6 Individual best doses fell in the range of 0.01-0.1 mg/kg 
7 DMTS-D refers to a variant of DMTS task that implements distractors. 
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1.5 Scope of This Study  
1.5.1 Alpha7 nAChR selective agonist (PHA-543613) 
The first experiment discussed in this thesis employed PHA-543613 9(N-[(3R)-1-Azabicyclo 
[2.2.2] oct-3-yl] furo [2,3-c]pyridine-5-carboxamide); an agonist highly selective for α7 nAChRs. 
This agonist has been under development for cognitive impairments associated with schizophrenia. 
PHA543613 has a high affinity for α7 nicotinic receptors (nAChR) and acts as an antagonist on 5-
HT3 receptors (Wishka et al., 2006). Because of negligible antagonist activity at both muscle and 
ganglion-like nicotinic receptors, rapid brain penetration and high oral bioavailability in rats 
(Wishka et al., 2006), PHA543613 was considered a good candidate for activating α7 nAChRs in 
this project. Only one non-human primate study exits in the literature which has used the same 
agonist for assessing changes in cognitive performance and its relevant neural activities (Yang et 
al., 2013). According to this study, PHA543613 showed a dose-dependent curve with optimal 
behavioral improvement occurring at low doses. Interestingly, the neural activity recorded by 
iontophoresis application of PHA543613 in the dlPFC also showed a dose-dependent effect on cell 
firing. The results of this study also indicated that α7 nACh receptors had a modulatory interaction 
with NMDA receptors and could enhance NMDA receptor-mediated glutamate transmission. 
Based on these results, the authors suggested that high dosages of agonists targeting cognitive 
deficits may result in non- specific effects on neuronal excitability and subsequent loss of 
beneficial effects and improvements.  
1.5.2 Alpha4 beta2 nAChR selective agonist (ABT-089) 
The second experiment utilized ABT-089 ([2-Methyl-3-(2-(S)-yrrolidinylmethoxy) pyridine 
dihydrochloride]), an agonist selective for α4β2 nACh receptors. This compound possesses good 
brain penetration and its pharmacokinetic properties have been studied in at least three animal 
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species including dogs, rats and monkeys (Rueter et al., 2004). This agonist has been under 
development for treatment of attention deficits associated with ADHD and Alzheimer’s disease 
and has been tested on children aged 6-12 and adults 55-90 years old.  ABT-089 has a high affinity 
for α4β2 nAChRs and its effects are weakened by non-competitive neuronal nicotinic receptor 
antagonist Mecamylamine (Rueter et al., 2004). ABT-089 has a low affinity for binding sites on 
cells that express muscle type nicotinic receptors. It also demonstrated a favorable safety profile, 
as shown by little or lack of cardiovascular and gastrointestinal irritations at plasma concentrations 
that are expected to be clinically beneficial (Rueter et al., 2004). This pharmacological agent was 
previously used in few non-human primates to test for its effects on cognitive tasks. In DMTS-D 
task with monkey subjects, intramuscular (IM) administration of ABT-089 in a wide range of doses 
(1.1, 2.2, 4.4, 8.8, and 17.7 microgram/kg) was associated with reduction in distractibility and 
increase in accuracy (Prendergast et al., 1998). In another DMTS task with monkeys, the same 
agonist improved performance in the subsets of trials that contained the longest retention interval 
and therefore were most difficult for subjects. The performance improvement was more robust in 
aged subjects (Decker et al., 1997). 
 
1.6  Hypotheses 
I implemented a systematic injection of two different doses of PHA-543613 and ABT-089 
agonists in one healthy rhesus monkey performing a feature based reversal learning task.  The 
complexity of the task design allowed me to address the effects of agonists on multiple 
behavioral components. This increased the chance of evaluating specific contributions of 
nicotinergic sub-receptors to goal directed behavior and selective attention. Specifically, I looked 
at how the two agonists affected performance accuracy and learning rate, filtering distraction, 
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motivation, reward-history based performance and proportion of error types including 
impulsivity and perseverative rates. I hypothesized that ABT-089 and PHA-543613 would at 
least have some differential effects across behavioral measurements. Based on previous studies, I 
expected to see increased performance accuracy in reversal learning and enhancement of 
attentional processes by either agonist. Since previous studies suggested attenuation of 
distraction in DMTS task by α4β2 agonists (Buccafusco et al., 2007; Howe et al., 2010; 
Prendergast et al., 1998), I predicted that ABT-089 would improve distraction filtering in our 
task. I also hypothesized that either agonist can potentially reduce perseverative tendencies. 
Studies by Jones et al. (2014) and Terry et al. (2016) suggested that perseverative errors can be 
attenuated by agonists selective for α7 and agonists selective for both α4β2 and α7 sub-receptors 
respectively. I did not expect to see any effects on motivation as previous studies did not show 
any changes in this measurement for either α4β2 (Guillem et al., 2011) or α7 (Hahn et al., 2011; 
Young, Meves, Tarantino, Caldwell, & Geyer, 2011). Several studies have reported inverted U-
shaped curve profile for nicotinergic agonists (Gould, Garg, Garg, & Nader, 2013; Kolisnyk et 
al., 2015; Redrobe et al., 2009; Wishka et al., 2006; Yang et al., 2013). This profile describes a 
non-linear relationship between dosage of pharmacological agents and their resulting behavioral 
changes. It states that the drug effects increase with dosage increase until they reach an optimal 
level at a particular point. Increasing the dose after this point leads to sub-optimal effects. Since I 
only used two doses, I could not make specific predictions in terms of an inverted U-shaped 
profile. However, I did expect to see changes in performance by at least one of the doses used for 
each agonist. 
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Chapter 2-Methods  
 
2.1 Subjects and Apparatus  
The data was collected from Monkey H, a 9-year-old adult male rhesus monkey (Macaca mulatta) 
subject who was previously trained on the task. Since March 2016, another 6-year-old male rhesus 
monkey known as Monkey K has been under training and still in progress. As part of training 
preparations, both subjects underwent surgeries to enable restraining head movements when 
performing the task. Following the surgery, the animals went through a recovery period during 
which they received necessary antibiotics and pain-management medications. Once recovered, 
animals were trained on the task with positive reinforcement such that they were rewarded with 
fluid (water or diluted juice) for each correct response to a trial. To maintain motivation throughout 
training and experiments, fluid intake was restricted during both experimental and control sessions. 
Unlimited access to primate biscuit chews was available to subjects and additionally, daily treats 
of nuts and dried fruits were provided. The subjects’ fluid and food intake, weight, and behavior 
such as agitation and aggression were monitored closely by the experimenter and animal care 
personnel. All the surgical, training, experimental and drug protocols were approved by animal 
care committee in York university and in accordance with the guidelines of Canadian Council on 
Animal Care.  
 The training and experiments took place inside a dark booth were the monkey was seated 
inside a primate chair, head-fixed and 65 cm away from a 21-inch LCD monitor. The visual stimuli 
were generated using customized MATLAB (Mathworks, R2014a) code. The experimental task 
and reward administration were presented and controlled by MATLAB and MonkeyLogic toolbox. 
The fluid reward was delivered through a sipper tube which was placed in front of the primate’s 
mouth and controlled by an air-pressured mechanical system.  The eye positon was tracked by 
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Eye-link 1000 eye tracking system at 500 Hz sampling rate and the pupil dilatation and saccade 
movements were recorded by Cheetah software. The stimuli and how they were used were 
different across the two subjects as the second subject has not fully learned the task yet. The 
following information is regarding the task that Monkey H performed. The details on the stimuli 
and the version of the task that Monkey K has been under training with are disclosed in Appendix 
A.1.  
 All the stimuli were displayed against a black colored background. The fixation point was 
a 15-pixel size grey circle in the center of the display. The stimuli consisted of two circular 
apertures with moving red/black and green/black gratings of 2° radius both equally spaced within 
5° away from the fixation points at right and left locations. The spatial frequency i.e. the motion 
speed of the movies was 1.20 cycles/degree. The location, movement direction of the stimuli and 
whether first the color or motion feature occurred prior to combination of both features were 
randomized throughout the sessions such that all possible 16 trial types were equally probable to 
occur during the task (Fig.11). The response target dots were both white and located 4° away up 
and downside of the fixation point.  
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Figure 11 All possible trial conditions based on location, color and motion direction types as well 
as the precedence of the last two features. No color-No motion, No motion-Color, Color and 
motion (N_NC_CM) refers to a trial type where after a stationary phase, first color is presented 
and then motion comes on. No color-No motion, No color-Motion, Color and motion 
(N_NM_CM) refers to a trial type with a reverse order of feature presentation i.e. first motion and 
then color. L and R refer to left and right location respectively. 
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2.2 Behavioral Paradigm 
The task aimed to evaluate reversal learning and attention in non-human primates with two 
differently colored visual stimuli (moving circles) on the screen. Multiple features including 
motion and color existed. The latter, would determine what stimulus would become rewarded in a 
block. Additionally, a dimming feature existed which served as a timing prompt for the subject to 
make a choice.  Dimming of the stimuli cued the response to the motion direction of the rewarded 
or target stimulus. Three different timing conditions were possible in that regard: 1) the target 
stimulus dimmed first and then the non-rewarded stimulus would dim. 2) both stimuli dimmed 
simultaneously and 3) the non-rewarded stimulus dimmed first and then the target stimulus would 
dim. The response that the animal had to make was to saccade to the motion direction of the target 
(either up or down). If the subject responded to the motion direction of a target stimulus at the 
wrong dimming event, the response was considered a non-choice error and not considered in the 
analyses. The task involved reversal of the rewarded feature value, in other words, the rewarded 
color would switch multiple times throughout the session (Fig.12-a). This change would occur 
under two circumstances: 1) within a minimum of 30 trials, the subject reached 85% in a 12-trial 
window average. 2) 50 trials were completed; regardless of how performance was during that 
block. Fig. 12-b shows the timing frame of each event during the task in milliseconds. Each time 
frames is numbered in sequence.  
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a 
   
b 
 
 
Figure 12 Feature-based reversal learning task: (a) depicts reversal of rewarded colors in a block-
wise fashion. Each color was selected for the first block of the session every other day. (b) shows 
the timing frame of each event. The task starts with fixating on a central gray point for about 500-
900 ms. Afterwards, a pair of grating stimuli appear on both sides of the central point and remain 
stationary for 400ms. After this period, there will be either a color onset (stimulus value) or a 
motion onset (action value). Either feature onset lasts about 500-900 ms and then both features 
will be combined. About 400-1000 ms later, either the target color or the distractor color dims for 
300 ms. If the distractor is dimmed first, then after a period of 100-550 ms, the target starts to dim 
for 300 ms. The subject should make a choice only when the target color is dimmed. The subject 
has 50-500 ms to make a choice and must maintain his fixation on the target for at least 50 ms. If 
the choice is correct, they will be rewarded, if not, a 1000 ms time-out occurs before the start of 
the next trial. 
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2.3 Experimental Procedure  
Monkey H did not receive either of the two drugs previously, however, he received Guanfacine 
(alpha2a-noradrenergic (a2a-NE) agonist) twice weekly about 14 months before the start of these 
experiments as part of a previous study conducted in the lab (Hassani et al., 2017). During this 4-
month period, he was not part of any experiments and had unlimited access to fluid and food.  Prior 
to the first experiment using PHA-543613 drug, Monkey H performed the task for three weeks to 
reach his baseline performance. The second experiment with ABT-089 started 3 months after the 
data was collected with PHA-543613 and the subject performed the task for a week prior to data 
collection to reach his baseline. No data was collected on Mondays as Monkey H would usually 
work unreliably on these days, probably because of being off work during the weekend. From 
Tuesday to Friday, total of two drug treatments of both doses were collected with at least one day 
between treatments. Assignment of the treatments was randomized such that each dose or vehicle 
could be administered at any day of the week to control for any biases that may have occurred 
because of variable performance throughout the week (Fig. 13).  Both drugs and vehicle were 
administered via intramuscular (IM) injection. The vehicle injections occurring between drug 
treatments were also considered for analyses as control sessions. The injections were administered 
by a lab technician and the experimenter was blind to the treatment conditions. During both 
experiments, the subject was given at least 50 minutes to perform the task. When collecting data 
with PHA-543613, the criterion for stopping the subject was lack of any trial completion within 
the first 5 minutes after 50 minutes of working. To optimize this criterion when collecting data 
with ABT-089, the criterion was changed so that the animal would be stopped if he completed 
fewer than 20 trials within the first 5 minutes after 50 minutes of working. For PHA-543613 
experiment, injection was administered 30±1 minute prior to start of the task. The time frame was 
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chosen as an estimate based on the rodent literature and the only non-human primate study in the 
literature (to the author’s knowledge) where the same drug was orally administered in rhesus 
monkeys 60 minutes prior to the experiment (Bali et al., 2015; Kolisnyk et al., 2015; Sadigh-
Eteghad, Talebi, Mahmoudi, Babri, & Shanehbandi, 2015; Wishka et al., 2006; Yang et al., 2013). 
For ABT-089 experiment, the IM injection occurred 10±1 minutes prior to the start of the task. 
This time frame was chosen based on previous non-human primate studies where the same drug 
was applied (Decker et al., 1997; Prendergast et al., 1998). All sessions were conducted at the same 
time of the day. The selected doses for PHA-543613 experiment were 0.125 and 0.250 mg/kg. 
These doses were chosen as an estimate from the rodent literature ((Bali et al., 2015; Kolisnyk et 
al., 2015; Sadigh-Eteghad, Talebi, Mahmoudi, Babri, & Shanehbandi, 2015; Wishka et al., 2006).  
The selected doses for ABT-089 experiment were 0.01and 0.02 mg/kg. These doses were chosen 
based on high and low values of the dose range previously tested in non-human primates.  Initially, 
0.04 mg/kg was selected as the higher dose for ABT-089; however, on the third collecting week, 
Monkey H experienced minor physiological side effects such as elevated heart rate and nausea 
which were attributed to the drug at the given high dose. Data collection with this dose was stopped 
immediately, and after a one-week recovery period, a lower dose (0.02 mg/kg) was selected to 
continue data collection. Following 8 and 12-week dose experimental protocols, the behavioral 
effects of PHA-543613 and ABT-089 doses respectively were tested. Data were excluded if they 
were collected from days when unexpected incidents such as staff intrusions, computer related 
problems etc. occurred. The first protocol provided 15 control sessions, 8 sessions with dose 0.250 
mg/kg and 7 sessions with 0.125 mg/kg dose for PHA-543613. The second protocol provided 20 
control sessions, 7 sessions with dose 0.02 mg/kg and 9 sessions with 0.01 mg/kg dose for ABT-
089. 
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Figure 13 Random assignment of weekdays to drug doses and control sessions. No drug or vehicle 
injection happened on Mondays as Monkey H was not motivated enough to perform reliably. On 
control days, the subject was injected with sterile water; On drug treatments, the subject could be 
injected with either of the doses. The red cross marks the days from which data could not be used 
in the analysis for reasons explained previously. 
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2.4 HPLC Analysis of Blood Serum 
To identify the peak concentration and the overall metabolism pattern of the drugs over time in 
blood, mass spectrometry HPLC analysis was conducted for both agonists. Nine blood samples of 
300 µL in total (baseline and 8 samples after injection) were extracted from 10-year-old male 
rhesus macaque monkey S, weighing 10 kg on the day of sampling. The samples were taken at the 
following time points: 1 minute before drug injection (baseline), 9,15,25,40,70,100,160 & 220 
minutes after injection. The higher drug dose (0.25 mg/kg) for PHA-534613 was considered for 
HPLC analysis while for ABT-089 the lower dose (0.01 mg/kg) was selected. Samples were 
centrifuged at 2000 rpm speed for about 40 minutes and after being spin filtered, stored for mass 
spectrometry HPLC processing.  
 The procedure was successful for PHA-543613, however, no ABT089 signal was observed 
in any of the blood samples and as a result no blood serum analysis could be obtained. It was 
possible that the injected drug dose was too low or the drug became completely protein bound in 
the blood and therefore would not have been able to pass through the spin filter. 
In previous literature, the plasma exposure of ABT089 was measured in baboons under both bolus 
intravenous (IV) injection and slow infusion in doses ranging 0.04-1 mg/kg (Chin et al., 2011).  
On average, the subject worked for 74 and 60 minutes during experimental sessions of PHA-
543613 and ABT-089 respectively. Therefore, the results from Chin et al. (2011) and HPLC 
analysis of PHA-543613 (Fig. 14 and 15), suggested that the peak concentration and the 
subsequent drop in blood concentration were captured within the testing session time for both 
pharmacological agents.   
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Figure 14 Measured PHA-543613 plasma exposure (mean ± standard deviation) in Monkey S. 
HPLC analysis of blood serum obtained over a period of 220 minutes after IM injection of 0.250 
mg/kg dose.  
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Figure 15 Measured ABT-089 plasma exposure (mean ± SEM) obtained under slow infusion vs 
bolus infusion in baboons. Red and blue data points refer to bolus and slow infusion injections 
respectively. The bolus infusion of IV injection is more comparable to the administration method 
used in this experiment. The lines represent the pharmacokinetic simulations conducted by the 
authors of the study  
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2.5 Data Analysis 
All the experimental data were analyzed with Matlab. To assess the effects of systematic injection 
of PHA-543613 and ABT-089 on feature based reversal learning, different aspects of behavior 
were defined and quantified as described below. In some analyses, a moderately small number of 
data points existed in the drug condition which was considerably fewer than control. Therefore, 
data across all control and drug sessions were compared using non-parametric Wilcoxon rank sum 
test for performance accuracy in different time windows, trial type subsets based on dimming event 
and reward history and number of reversal blocks and rewarded trials.  In addition, two-sample z-
test for comparing proportions, and randomization test when correction for multiple comparison 
was needed were used.  
 Temporal variation of drug effects on performance. Trial by trial performance was 
estimated by using expectation maximization algorithm (See Appendix B.1 for more details) 
developed by Smith (2004). Different overlapping time windows after the task started were 
selected to evaluate the temporal effects of drugs on behavior. The time windows included: 0-25, 
12.5-37.5, 25-50, 37.5-62.5 minutes (Fig. 16).  Performance accuracy was evaluated in I) 
throughout trials 1-25; II) During the learning period i.e. all trials up to the estimated learning trial 
by the algorithm; III) After the learning period i.e. all trials after the estimated learning trial up to 
trial 25. Different behavioral aspects such as speed of learning and asymptotic performance levels 
after learning were measured.  
 Dynamics of performance including learning speed and net increases in performance were 
measured via parameters of a hyperbolic ratio function fit to performance curves. The parameters 
of interest to make comparison between experimental and control sessions were C-50 (trial to reach 
half maximal of performance, exponent (slope) and R-max (maximum increase in performance 
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since baseline performance). A randomization test was used to evaluate the significance of the 
difference in performance between the experimental and control sessions (See Appendix B.2 for 
more details).  
 Distraction filtering. Defined as the performance accuracy in trials were dimming of both 
stimuli occurred simultaneously. Here, performance was calculated as the proportion of correct 
choices within a backward trial window of 5 averaged across all blocks of a session (Fig. 17). In 
comparison to trials where dimming of the two stimuli did not happen simultaneously, 
performance in the same dimming trial type required a higher level of attentiveness to filter 
distraction. All dimming trial types were presented with the same ratio i.e. 1/3 each.  
 Motivation. Defined as total number of blocks performed and rewarded trials which would 
indicate the amount of fluid earned by the subject. Blocks were categorized as learned and not-
learned; the latter defined as blocks not identified to be learned by the EM algorithm or their 
corresponding learning trial computed by the EM algorithm was higher than 24.  The proportion 
of learned to total reversal blocks were computed as well and compared to each other with two 
sample proportions z-test (See Appendix B.3).  
 Effects of reward history in learning maintenance. Trials were grouped to 8 categories 
based on the number of consecutive rewarded trials after an unrewarded/error trial. The proportion 
of correct trials in each category was calculated to compare the effect of reward history on 
performance of a given trial. This analysis was conducted in a previous non-pharmacological study 
to investigate the mechanism underlying the role of anterior cingulate in reinforcement-guided 
behavior (Kennerley, Walton, Behrens, Buckley, & Rushworth, 2006).  
 Various Error Types. Error trials consisted of premature responses in time frames 2-4 and 
4-6 as well choice-based errors (i.e. response to an incorrect stimulus). Proportion of different error 
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types to total errors in a session were computed. Pre-mature responses in time frame 2-4 were 
considered motivation-based errors. Motivation-based errors were defined as fixation breaks after 
stimulus onset (i.e. time frame 2) but before time frame 4 (i.e. the time frame when all the necessary 
information for making a response is available). 
 Pre-mature responses in time frame 4-6 were considered impulsivity-based errors. 
Impulsivity errors were defined as the number of trials in which erroneous saccades were made 
towards a stimulus after the onset of both motion and color feature (i.e. time frame 4) but before 
the dimming of that stimulus (i.e. time frame 5 or 6).  The choice-based errors were analyzed 
within a successive pattern and termed as successive errors. These errors were defined as the 
number of successive choice errors ranging from 1-8 trial numbers following a correct trial.  
For all analyses, performance was looked at within reversal blocks only i.e. the first block of the 
day was removed from analyses. Additionally, blocks with fewer than 16 trials (i.e. last block of 
the day where sometimes subject would not complete it) were excluded from the analysis.  
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Figure 16 Arrangement of time windows after the task starts for investigating the temporal effects 
of drug treatments on behavior. Depicted are the main four overlapping periods selected for the 
analysis aligned against the drug concentration curve over time for PHA-543613, 250 mg/kg dose. 
Lines 1-4 refer to 0-25, 12.5-37.5, 25-50 and 37.5-62.5-minute time windows. 
 
 
 
 
 
 
  52 
 
 
 
 
 
 
 
 
Figure 17 Proportion of correct choices calculated for each dimming type. Backward trial window 
of 5 were selected across all blocks of a session. Colors green, blue and red represent dim type 
first, same and second respectively. The proportion of correct to incorrect choices were extracted 
for each dimming trial type that existed within a given window. For instance, in window (1), the 
correct proportion at trial 1 for first dimming trial type was computed as: 2/5=0.4, for same 
dimming trial type as: 3/6= 0.5 and for second dimming trial type as: 3/4=0.75. 
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Chapter 3-Results 
3.1 Temporal Effects of Selective nAChR Agonists on Performance  
Performance in learned reversal blocks following administration of α7 and α4β2 agonists was 
compared with that of control sessions over all sessions (Fig. 18 and 19). Performance accuracy 
was analyzed in four different but overlapping time windows: 1) 0-25, 2) 12.5-37.5, 3) 25-50 and 
4) 37.5-62.5 minutes after the task started. Tables 3 and 4 show the number of blocks performed 
in all treatment and control days during time windows 1-4 and over the whole session. Results 
showed there was no difference in performance averaged across all trials between either drug doses 
and control when data was analyzed from blocks over the whole session (Wilcoxon ranksum, p> 
0.05). However, within the four selected time windows, average performance was higher under 
PHA-543613 (0.250 mg/kg dose) than control conditions in 0-25-minute period only (Wilcoxon 
ranksum, p=0.024). The lower dose did not result in any significant increase or decrease in the 
performance accuracy compared to control sessions (Wilcoxon rankusm p>0.05). As for ABT-089 
treatments, average performance was not significantly different than control sessions in either dose 
regimen over the whole session or selected time windows (Wilcoxon ranksum, p>0.05). As 
mentioned earlier, performance was also averaged across all trials during and after learning. The 
estimated learning trials from both control and drug sessions for a given time window were 
averaged to set the trial range for during and after learning periods. This resulted in the following 
average learning trials for performance over the whole session and within time window 1-4 
respectively: PHA-543613 (dose 0.25 mg/kg) and control:  12, 7, 7, 8 and 8; PHA-543613 (dose 
0.125 mg/kg) and control: 12, 7, 8, 8 and 8;  ABT-089 (dose 0.02 mg/kg) and control: 9, 5, 6, 7 
and 7; ABT-089 (dose 0.01 mg/kg) and control: 10, 6, 6, 7 and 6. Average performance during 
learning was not different between either PHA-543613 dose treatments and control sessions when 
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analyzing the data over the whole session or within time windows 1-4 (Wilcoxon ranksum, 
p>0.05). Similarly, during learning performance was not significantly different than control in 
ABT-089(0.02 mg/kg) treatment over the whole session or in either time windows (Wilcoxon 
ranksum, p>0.05). However, the lower dose treatment showed significantly lower average 
performance during learning within 12.5-37.5-minute time window (Wilcoxon rankusm, p=0.01).  
Next we analyzed after learning performance in all drug treatments and control sessions. In PHA-
543613 (0.25 mg/kg) treatment, after learning performance was significantly higher than control 
within 0-25 and 12.5-37.5-minute time windows only (Wilcoxon ranksum, p=0.031 & p=0.03 
respectively). The lower dose treatment was not associated with any significant difference in 
performance compared to control sessions over the whole session or within either time window. 
Similarly, neither ABT-089 dose regimen resulted in any significant difference in after learning 
performance compared to control sessions in any period (Wilcoxon ranksum, p>0.05).  
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Table 3 Number of blocks performed by Monkey H per each condition for all PHA-543613 
treatments and control days during selected four time windows and over the whole session. Only 
reversal blocks that were identified as learned were quantified and used for the analysis. Note that 
consistent across all conditions, fewer blocks were performed later throughout the session i.e. the 
last time window. 
 
Time interval PHA-543613  
(0.25 mg/kg) 
PHA-543613  
(0.125 mg/kg) 
Control 
0-25-minute 30 25 50 
12.5-37.5-minute 31 21 52 
25-50-minute 29 19 39 
37.5-62.5-minute 25 16 29 
Whole session period 75 72 122 
 
 
 
Table 4 Number of blocks performed by Monkey H per each condition for all ABT-089 treatments 
and control days during the selected four time windows and over the whole session. Table 
descriptions are the same as Table 3. 
 
Time interval ABT-089  
(0.02 mg/kg) 
ABT-089  
(0.01 mg/kg) 
Control 
0-25-minute 26 36 83 
12.5-37.5-minute 29 33 74 
25-50-minute 21 30 61 
37.5-62.5-minute 8 19 42 
Whole session period 48 84 166 
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Figure 18 Performance across all blocks over the task session and within four selected time 
windows after the task started: PHA-543613 versus control. Panels (a-e) show the performance 
difference curves between PHA-543613 treatments and control sessions. All trials up until average 
learning trials are analyzed for “during learning” performance and the remaining trials after this 
period are analyzed for “after learning” performance. Panels (f-j) show average performance 
accuracy across all trials (T), during (D) and after learning (A). Panel “f” shows higher average 
performance compared to control accuracy across all trials within time window 1(Wilcoxon 
ranksum, p=0.024) and after learning within the time windows 1-2 (Wilcoxon ranksum, p=0.031 
& p=0.030) under PHA-543613 (0.25 mg/kg). Error bars show 95% confidence intervals.  
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Figure 19 Performance across all blocks over the task session and within four selected time 
windows after the task started: ABT-089 versus control. Panel descriptions are the same as Fig. 
17. Panel “g” shows lower average performance compared to control accuracy during learning 
within in time window 2 (Wilcoxon ranksum, p= 0.01) under ABT-089 (0.01mg/kg). Error bars 
show 95% confidence intervals. 
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 To validate the previous finding regarding enhanced performance under the high dose of 
PHA-543613 with an additional metric, a function fitting approach was used to assess other 
dynamics of the performance. A hyperbolic ratio function (aka Naka-Rushton equation) was fit to 
the performance curves in all learned reversal blocks for each condition over the whole session 
and time windows 1-4. The following equation used in this analysis was reproduced from Williford 
and Maunsell (2006) with four parameters including Rmax, C50, n and m.  
        
Rmax is the maximum attainable y value; In case of behavioral data analyzed in this thesis, Rmax 
is the difference between the maximum and minimum probability of being rewarded defined as 
parameter “m” in the function. The exponent “n” parameter represents how rapidly the y value 
(i.e. the probability of being rewarded) increases from at minimum level (i.e. chance level 
performance at the first trial in this case) to the saturating point (i.e. Rmax+m) and finally C50 
represents the trial number at which the y value or probability of being rewarded is half maximal. 
This function was chosen to model the data as it included the parameters that defined the behavior 
of the data well i.e. it corresponds to the rising pattern of the performance which stabilizes or 
saturates at a certain level. Consequently, the parameters allow for meaningful interpretations of 
the data. For instance, a left shift of C50 would indicate learning a block in fewer number of trials. 
Acceptable ranges were chosen for all parameters from which randomly an initial value was 
assigned to estimate each parameter: 
Rmax: the difference between minimum and maximum of probability of being rewarded were 
computed across all blocks. The initial “Rmax" value was randomly chosen from this range. 
m: the minimum and maximum of the probability of being rewarded at the first trial across all 
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blocks were computed. The initial m value was randomly chosen from this range. 
C50: the minimum and maximum of the trial number at which the probability of being rewarded 
is half maximal across all blocks were computed. The initial “c50” value was randomly chosen 
from this range. 
n: the initial “n” value was chosen within 1-3 range. 
 Randomization tests to determine the significance difference for the parameters confirmed 
that there was no significant difference between ABT-089 (both doses) and PHA-543613 (0.125 
mg/kg) and their corresponding control sessions (p>0.05). However, results showed that within 
the 0-25-time window, PHA-543613 (0.250 mg/kg) had a significantly lower value of C50 
compared to control sessions (p=0.0341) (Fig. 20). No significant differences were observed for 
other parameters in either time windows for the same treatment (p>0.05) 
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Figure 20   Hyperbolic-ratio function fit to performance curves within time window 1 under PHA-
543613 (0.25 mg/kg) treatment and control. (a): depicts function fit to performance curve within 
0-25-minute time window. The histogram shows the null distribution resulted from randomization 
procedure; Red lines represent 97.5 and 2.5 percentiles of the distribution and the black line the 
observed test statistics. (b): demonstrates the C50 parameters estimated by the function within all 
four time windows for the same drug treatment and control. This parameter was significantly lower 
under drug condition in time window 1 (p=0.0341). 
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3.2 Effects of Selective nAChR Agonists on Distraction Filtering  
Performance accuracy was averaged across all 25 trials for all dimming type trials under drug and 
control conditions (Fig. 21 and 22). Under PHA-543613 treatments, the average performance 
accuracy was not significantly different than control in either dimming trial type (Wilcoxon 
ranksum, p>0.05). As for ABT-089 treatments, the higher dose yielded higher average 
performance accuracy than control only when both stimuli dimmed simultaneously (Wilcoxon 
ranksum, p=0.033). The lower dose of the same treatment was not associated with any significant 
difference in either dimming trial type (Wilcoxon ranksum, p>0.05).  
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Figure 21 Average daily performance within each dimming trial type in PHA-543613 experiment. 
The panel on the left side shows performance difference curves between drug treatments and 
control sessions under first, same and second dimming trials. Trial numbers refer to the rank of 
that trial compared to all other trials from the same dimming subset; for example, third trial in dim 
first refers to the third “first dimming” trial that occurred in the block. The panel on the right side 
depicts the averaged performance across trials 1-25 in each corresponding performance difference 
curve. Neither drug doses affected performance in any of the dimming trial types.  
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Figure 22 Average daily performance within each dimming trial type in ABT-089 experiment. 
Panel descriptions are the same as Fig. 20. Average performance in same dimming trial type only 
was significantly higher than control under ABT-089 (0.02 mg/kg) treatment (Wilcoxon ranksum, 
p=0.033)  
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3.3 Effects of Selective nAChR on Motivation 
The average number of reversal blocks were 11.8, 12.7 and 11.3 for PHA-543613 (0.25 mg/kg), 
PHA-543613 (0.125 mg/kg) and control respectively and not significantly different from each 
other (Wilcoxon ranksum, p>0.05). Proportion of learned blocks in either PHA-543613 treatments 
were comparable to that of control (z test, p>0.05). In general, the subject tended to perform fewer 
number of blocks during the second protocol. The average daily number of total reversal blocks 
were 7, 10 and 9.7 For ABT-089 (0.02 mg/kg), ABT-089 (0.01 mg/kg) and control. Monkey H 
performed significantly fewer number of blocks than control when injected with higher dose of 
ABT-089 (Wilcoxon ranksum, p=0.0255). However, the proportion of learned blocks in ABT-089 
(0.02 mg/kg) treatment was significantly higher than control (z test, p=0.018) (Fig. 23).  
 In addition to the total number of reversal blocks performed, the average earned reward 
was compared across drug treatment and control conditions using total number of rewarded 
choices throughout the whole session. Average number of total rewarded choices were 342, 401 
and 354 for PHA-543613 (0.25 mg/kg), PHA-125 (0.125 mg/kg) and control respectively. There 
were no significant differences between either drug treatments and control (Wilcoxon ranksum, 
p>0.05). Likewise, average number of rewarded choices were similar across both drug treatments 
and control in ABT-089 experiment (Wilcoxon ranksum, p>0.05). Average number of total 
rewarded choices were 212, 304 and 264 for ABT-089 (0.02 mg/kg), ABT-089 (0.01 mg/kg) and 
control respectively.  
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Figure 23 Average number of reversal blocks under all drug treatments and control sessions. 
Percentages depicted in each bar represents the average proportion of learned blocks (as identified 
by the EM algorithm). Total number of reversal blocks and proportion of learned blocks under 
both PHA-543613 treatments and control were comparable to each other. Total number of reversal 
blocks was significantly lower under ABT-089 (0.02 mg/kg) compared to control (Wilcoxon 
ranksum, p=0.0255). In contrast, the proportion of learned blocks was higher under the same 
treatment than control (z-test, p=0.018). The error bars represent 95% confidence intervals. 
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3.4 Effects of Selective nAChR on Reward History Based Performance 
As seen in Fig. 24, The effect of reward history on performance of a given trial in each of the 8 
categories was comparable across all drug treatments and control sessions and not significantly 
different from each other (Wilcoxon ranksum, p>0.05). It should be noted that by definition, the 
categories with higher number of consecutive correct trials would occur much less frequently 
compared to categories with low numbers of these trials. Looking at PHA-543613 (0.250 mg/kg) 
for instance, there were only an average of 15 trials in E+C8 category compared to 109 in E+C1.  
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Figure 24 Reward history based performance under all drug treatments and control sessions. 
Panels a-d show performance curve defined as proportion of correct choices within each trial 
category. In all conditions, an enhancing trend in performance existed such that average proportion 
increased over the trial categories with higher number of correct choices after an error. However, 
this performance enhancement was consistent and not different across all drug treatment and 
control sessions (Wilcoxon ranksum, p> 0.05). The bar graphs e-g represent the average number 
of trials in each category. Error bars show 95% confidence intervals.  
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3.5 Effects of Selective nAChR on Error Types 
Fig. 25 shows the proportion of each error type within a condition. The proportion of each error 
type i.e. successive-based errors, impulsivity-based errors and fixation break-based errors to total 
error types were computed. Generally, fixation break errors constitute the greatest proportion of 
all error types (on average 53.5 % across all drug and control conditions) while successive errors 
constitute the lowest proportion (on average 15 % across all drug and control condition). Results 
showed that the proportion of error types are very similar and consistent across all drug treatments 
and control sessions (Wilcoxon ranksum, p>0.05). 
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Figure 25 Proportion of three different error types in all drug treatment and control sessions. 
Fixation break errors constituted the highest error type across all conditions while impulsivity 
bases errors constituted the lowest. Neither drug treatment modulated any of the error types 
(Wilcoxon ranksum, p>0.05). 
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Chapter 4-Discussion 
This thesis describes a project with qualities that distinguish it from the previous studies 
investigating the effects of nicotinic sub-receptors in animal models. First, the task used in this 
study allowed me to dissociate the effects on learning and attentional filtering from other 
motivational and behavioral measures of behavioral flexibility. Second, the dose selection protocol 
allowed a rapid identification of an optimal dose associated with performance improvement and a 
dose with no behavioral effects, thereby avoiding the complications that follow a fixed treatment 
schedule. Finally, multiple analysis approaches were used to evaluate behavioral indices and 
validate the main findings. 
 Overall, I found that the higher dose of each agonist emerged to be a dose that led to 
significant performance improvements. The behavioral enhancement induced by each agonist was 
unique and specific to different aspects of the task. The optimal dose of α7 receptor agonist 
increased overall performance accuracy and sped up learning of reversals in reward contingencies, 
but only within the first 25 minutes of the task when substantial concentration of the agonist was 
still present in the plasma. The optimal dose of α4β2 agonist was associated with improvement in 
trial types where filtering of distracting stimuli was most difficult. Neither agonist affected other 
behavioral measurements including motivation, impulsivity or perseverative rates. The lower dose 
of the α4β2 agonist was associated with lower performance accuracy during the learning period 
within a 12.5-37.5-minute time window after drug administration.  
4.1.1 Selective Nicotinic Receptor Modulation of Distractor Filtering  
In order to investigate the effects of selective nicotinergic agonists on control of interference from 
distractors, we averaged proportion of correct choices in each of the three existing subsets of trials 
and specifically, looked at trials in which both stimuli signaled the response simultaneously.  
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 Proportion of correct choices in trials where both stimuli signaled the response at the same time 
was not significantly affected by either dose of PHA-543613. In contrast, proportion of correct 
choices was significantly increased in this subset of trials with the optimal dose of ABT-089 (See 
Fig. 22). In comparison with other trial types where the target stimulus signals the response prior 
to or after the distracting stimulus, trials in which both target and distracting stimuli signal the 
response simultaneously, had the highest attention demand to filter distraction. As such, this 
finding is consistent with my hypothesis that the α4β2 agonist would improve the ability to filter 
distracting stimuli. It is also consistent with previous rodent literature showing that α4β2 agonists 
enhanced performance in dSAT task (Howe et al., 2010); and with non-human primate studies 
where three different α4β2 agonists including ABT-089 improved performance accuracy in 
DMTS-D task (Buccafusco et al., 2007; Prendergast et al., 1998).   
 Interestingly, Prendergast and colleagues (1998) initially tested ABT-089 in a regular 
DMTS task and found no significant effects on performance. The authors then proceeded to test 
the drug in the more demanding DMTS-D task which includes distracting stimuli in delay periods. 
Consequently, they found that ABT-089 increased average number of correct choices in this 
variant of the task. Similarly, Howe et al. (2010) did not find any performance accuracy 
enhancement in regular version of SAT task but found increased hits in the variant with intervening 
distracting stimuli. In terms of effective doses, the optimal dose of ABT-089 in this thesis (0.02 
mg/kg) was comparable to the highest effective dose of ABT-089 in Prendergast et al., (1998) 
study (i.e. 0.018 mg/kg) (for details on selected doses see Table 2). 
 The results of this thesis showed that α4β2 agonist can enhance control of interference from 
distractors and attenuate the influence of distractors on performance accuracy. This finding is 
consistent with those of other studies which suggest that α4β2 receptors may be more prominently 
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involved in mediating attentional processes when cognitive load is augmented (Buccafusco et al., 
2007; Howe et al., 2010; Prendergast et al., 1998). Such enhancement effects on attention filtering 
by α4β2 agonists can be potentially mediated by evoked cholinergic transients in the PFC (Parikh 
et al., 2007) and facilitation of interactions between glutamatergic-cholinergic transients 
(Hasselmo & Sarter, 2011;Parikh et al., 2010).  
4.1.2 Selective Nicotinic Receptor Modulation of Reversal Learning 
Of the two agonists used in this study, the optimal dose of α7 agonist led to increase in probability 
of rewarded choice over all trials of a block within time windows that corresponded to the period 
when the drug was roughly at its peak concentration. The performance accuracy was enhanced 
most robustly in the after learning period in 0-25 and 12.5-37.5-minute time windows, suggesting 
a better maintenance of learning by PHA-543613 (See Fig. 18 f and g). Unlike 12.5-37.5-minute 
time window, performance accuracy in 0-25-minute time window was significantly enhanced 
throughout the whole block (See Fig. 18 a and f).  Although the increased performance accuracy 
in the during learning period did not reach statistical significance, assessment of performance over 
all trials via hyperbolic-ratio function fitting showed that Monkey H reached half maximal of his 
performance in fewer trials compared to control sessions. Therefore, these results suggested that 
Monkey H learned block reversals faster during trials of the 0-25-minute time window. While one 
non-human primate study suggested improved performance accuracy in a spatial reversal learning 
task (Terry et al., 2016), neither rodent nor other non-human primate studies have reported more 
efficient reversal learning before. The difference in the findings of this thesis and previous 
experiments can be explained by how the reversal learning tasks were designed across the studies. 
In my thesis, I used a reversal learning task in which the subject performed serial reversals each 
daily session. This is in contrast with other studies in which subjects would perform one reversal 
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of an exemplar set per session. Rygula and colleagues (2010) proposed that exposure to learning 
reversals can result in utilizing strategies for optimal performance and showed that different brain 
regions of the PFC are recuited when marmosets reversed between a new set of stimuli than the 
same set several times.  Another explanation could be temporal intervals within which the data 
was analyzed. In this project, both performance accuracy and faster learning were time-locked to 
early time windows. On the contrary, when analyzing the data over the whole session, these effects 
were non-existent. Previous selective nAChR agonist studies with reversal learning in both rodents 
and non-human primates analyzed the data within the overall session only and did not consider 
different time intervals. However, agonist-induced improvement in specific time blocks has been 
reported by previous studies using attentional tasks (5-CSRTT and SAT) and α7 pharmacological 
agents (Hahn et al., 2011; Rezvani et al., 2009). Similar to my results, the time windows that the 
behavioral effects were reported also paralleled the peak concentration of drugs.  
 Performance accuracy was not enhanced with ABT-089 over any time window. In fact, the 
lower dose led to decrease in performance accuracy in the during learning period within 12.5-
37.5-minute time window. However, such a decrease in performance within this time window did 
not result in slower learning of the reversals.  
 In summary, we found that PHA-543613 broadly improves learning performance when the 
drug is at its peak concentration in the plasma. This is unlike the enhancing effects of ABT-089 
which were specific to a subset of trials. Stimulation of α7 receptors has been proposed as a 
possible mechanism underlying ACh release in response to relevant events and subsequent 
strengthening of PFC network connectivity (Arnsten et al., 2010). Thus, an enhanced 
representation of relevant features in an environment (e.g. in this task  color) can be a potential 
mechanism underlying the overall increased performance accuracy by α7 agonist PHA-543613. 
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4.1.3 No Net Influence on Motivation, Impulsivity or Perseveration 
The agonists used in this study did not change all aspects of performance in a healthy subject. 
Motivation was not affected by either sub-receptor agonist. While Monkey H performed 
significantly fewer reversals blocks under the optimal dose of ABT-089, his earned reward i.e. 
fluid was comparable to control sessions. This is because with drug treatment, Monkey H 
performed the blocks more efficiently (as seen in higher proportion of learned blocks) and while 
doing fewer reversals, completed similar number of rewarded trials in both conditions. Therefore, 
consistent with previous studies, neither agonist impacted motivation (Guillem et al., 2011, Hahn 
et al., 2011; Young, Meves, Tarantino, Caldwell, & Geyer, 2011).  
 Neither agonists in this thesis affected impulsivity, motivation-based and successive errors 
(See Fig. 23 and 25). Hoyle and colleagues (2006) showed that depending on the variability of 
inter-trial intervals, lack of α7 subunit expression in mice can increase premature responses in 5-
CSRTT task. When inter-trial intervals were fixed and no punishment delay period (time-out) 
followed these choices, the KO animals showed increased impulsivity. However, when inter-trial 
intervals were variable and time-outs included, KO subjects were not more impulsive than the 
wildtype. Therefore, other factors such as temporal prediction abilities may have been involved in 
the initial observed increased premature responses rather than impulsivity (Hoyle et al., 2006). The 
vast majority of 5-CSRTT studies limit themselves to reporting the percentage of accuracy and 
omission errors. Additionally, due to the nature of SAT and ID/ED set shifting tasks, it is not 
possible for animals to respond prematurely and as such, studies with these tasks do not report 
impulsivity. Consequently, effects of selective nicotinergic sub-receptors on impulsive behavior 
are not extensively investigated in either rodents or monkeys. For this project, I looked at pre-
mature responses that occurred after the animal was exposed to all the necessary information for 
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making a response (i.e. color and motion) but before the go signal to respond (i.e. dimming of the 
stimulus). It should be noted that this is different from the time frame within which premature 
responses are calculated in 5-CSRTT which is the period before any stimulus (light cue) 
presentation.  
 I also did not find any drug-induced effects on fixation breaks in the time interval after 
stimuli presentation and before the display of all the necessary information for making a response. 
The lack of any significant effects on fixation breaks within this period implies that completing 
fewer trials with the optimal dose of ABT-089 was mainly due to lack of initiating a trial rather 
than breaking fixation when the stimuli were already displayed on the screen.  
  Finally, another error type that was looked into consisted of successive errors. These errors 
were counted after a correct response and could go as up as 8 consecutive choice-based error trials 
where Monkey H responded to the direction of the distracting stimulus. This measurement was 
independent of trial onset relative to the start of the block i.e. it was not limited to when the blocks 
just switched but included all errors of this nature throughout the whole block. Results did not 
show any drug-induced changes with either agonist and therefore, did not support my hypothesis 
that either agonist can potentially attenuate perseverative tendencies. This finding is in consistency 
with that of Gould et al. (2013) but at odds with those of Terry et al. (2016) and Jones et al. (2014). 
The discrepancy between results can be explained by how the errors were evaluated in each study 
i.e. whether the experimenters counted errors within a certain number of trials after the reversal 
(Jones et al., 2014; Terry et al., 2016) or counted them throughout all trials (Gould et al., 2013). 
Another explanation can be the use of animals whose performance were impaired by injection of 
pharmacological agents such as ketamine and phencyclidine (PCP) that are known to cause 
cognitive deficits  (Jones et al., 2014; Terry et al., 2016). It is also possible that the selected drugs, 
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doses and timing of drug administration led to these different findings. For instance, Terry et al. 
(2016) used an α4β2 agonist which also strongly activated α7 receptors and administered the drug. 
While Terry et al. (2016) found attenuation of errors by all doses, Jones et al. (2014) found a dose-
dependent effect with PNU-282987 (an α7 agonist with no interaction on α4β2 receptors) such that 
only the lowest dose was effective in reducing perseveration errors. However, the other effective 
dose of the study which similar to the lowest dose led to fewer trial to performance criterion in ED 
shift, failed to attenuate perseveration errors.  
 In summary, our findings show that nicotinic α4β2 and α7 sub-receptors do not improve 
performance through mediating motivation and different error types. Our findings suggest that the 
enhanced reversal learning mediated by α7 receptors occur in the absence of modulation of 
perseveration tendencies. Our findings also suggest that enhanced attentional control mediated by 
α4β2 receptors is independent of motivational factors. This finding is in consistency with a 
previous study which showed that increased response accuracy by non-selective nicotinic agonist 
was different from motivational-induced performance accuracy in rodents performing a 5-CSRTT 
task (Bizzaro and Stolerman, 2003). 
4.2 Limitations  
4.2.1 Lack of Washout Period in a Subset of Datasets  
It is assumed that using a drug on one day still has a carryover effect on subsequent days and could 
influence behavior (Jerry J. Buccafusco, Letchworth, Bencherif, & Lippiello, 2005). Therefore, 
most pharmacological experiments consider washout periods in between treatment sessions. 
During these periods, no drug or control data are collected. However, no washout days were 
considered in between some of the drug and control sessions in the current study. This is unlike 
previous nicotinergic studies where usually a minimum of 1 washout day was considered (see for 
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example Jerry J. Buccafusco et al., 2007). However, it should be noted that in those studies, the 
control condition only takes place in the first day of the week and as such, drug treatments are also 
assigned to certain days of the week. This design does not control for behavioral variability of the 
subject which may rise as a result of performing in different days. Additionally, it does not allow 
for a blinded experiment and as such subjective biases may interfere with the data collection and 
result interpretation. 
 Based on the HPLC analysis for PHA-543613, the drug levels in blood serum should be 
back to baseline in less than 5 hours. Inferring from the results obtained with baboons (Chin et al, 
2011) it can be expected that similar to PHA-543613, the plasma concentration of ABT-089 is 
most likely back to baseline in less than 24 hours. Decker and colleagues reported no behavioral-
induced effects of ABT-089 in adult monkeys performing DMTS task which were assessed 24 
hours after the IM drug administration. More importantly, aged monkeys in whom ABT-089 
enhanced performance accuracy 10 minutes after drug injection, did not maintain the enhanced 
performance when evaluated 24 hours later. Thus, in-between treatment sessions in my study 
would be either comparable to control days that were scheduled at the beginning of the week or 
given the overall enhancing effects of both agonists, would be accompanied by a slight 
improvement in performance. Consequently, the results may have been even stronger if control 
days only happened at the beginning of the working week. Overall, while the scheduling of 
experimental and control conditions was not the most optimal in my thesis, it prevented problems 
common to fixed scheduling of treatments. 
4.2.2. Nicotinergic Specificity of Behavioral Improvement 
While the selected agonists in this study were mainly selective for a particular nicotinergic sub-
receptor, they also interacted with other nicotinic or non-nicotinic receptors. Consequently, the 
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findings of this study should be interpreted with caution. PHA-543613 acts as an agonist on α7 
nACh receptors but also acts as an antagonist on 5-HT3 serotonin receptors. Therefore, it could be 
possible that it was the antagonizing effects on 5-HT3 which led to increased performance 
accuracy and faster reversal learning. Previous studies with RG-3487 (a nicotinic agonist which 
similar to PHA-543613 is an agonist and antagonist for α7 and 5-HT3 receptors respectively) 
provided evidence that the cognitively enhancing effects of this agonist is most likely due to the 
drug acting on α7 nACh receptors (Boess et al., 2007; Wallace et al., 2011). These studies used 
MLA (an α7 antagonist) and observed that the performance improvement induced by RG-3487 
was blocked by this α7 receptor antagonist. Therefore, while possible contribution of 5-HT3 
receptors to the findings of my study about the effects of PHA-543613 cannot be completely ruled 
out, it is more likely that effects were mediated by activation of α7 receptors.  
ABT-089 acts as an agonist on both α4β2 and α6β2 receptors, and as an antagonist on α3β4 
receptors, which are expressed in the peripheral nervous system. In terms of interaction with α7 
receptors, ABT-089 is shown to have a complex interaction with α7 receptors as it can both activate 
and desensitize them (Rueter et al., 2004), however, this interaction is reported to be insignificant 
(Lin et al., 1997; Marks, Wagemana, Gradya, Gopalakrishnanb, & Briggs, 2009; Rueter et al., 
2004).  
It could be possible that the effects found with ABT-089 in this thesis can be attributed to 
activation of α6β2 receptors. However, studies with other α4β2 agonists such as ABT-418 and 
ABT-594 which do not interact with α6β2 receptors, have also reported similar effects i.e. both 
agonists improved performance accuracy when distracting stimuli were included in the DMTS task 
(Buccafusco et al., 2007; Prendergast et al., 1998). Therefore, it is likely that the pro-cognitive 
effects found with ABT-089 in the current study are mediated by activating α4β2 sub-receptors. 
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4.2.3 Overly Trained Subject 
Extensive exposure to discrimination between stimuli can facilitate reversal learning in animals. 
Often, subjects are tested on reversals shortly after reaching a certain performance criterion and 
therefore, over-training effects are not usually of concern in reversal learning tasks (Gilmour et al., 
2013). In this thesis, data was collected from Monkey H which was over-trained on this task and 
used for 2 previous experiments in the lab prior to data collection for this project. The effects of 
over-training are evident in the observed high performance accuracy, in particular, in a subset of 
trials where the target stimulus dims after the distractor.   
 As a result of this over-training, it is possible that lack of significantly enhanced 
performance in the second-dim trial types could be due to the already ceiling performance in this 
subset of trial types. It is also possible that lack of effects on reversal learning was not observed 
with ABT-089 as the subject was already performing the blocks at a fast rate. Additionally, over-
training can also explain the observed trends in the successive errors. When I started working with 
Monkey H, he would usually have more successive errors after a period of responding to the 
correct stimulus rather than at the beginning of the block when he was faced with the reversed 
reward contingencies.  Such pattern indicates that he was likely predicting and expecting a change 
in the block and was already responding to the other stimulus which would be rewarded in the next 
block.  
 Longer periods of  training can also reduce the frequency of premature responses in over-
trained subjects (Hoyle et al., 2006). Therefore, lack of any observed effects on premature 
responses after color and motion features were presented can be due to higher proficiency of 
Monkey H in performing this task compared to his less experienced days.  
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4.2.4 A Single Case Study  
The current project is a rigorous study of a single case of a young male adult   monkey. This is in 
unlike other studies reviewed in this thesis which used multiple subjects. However, in some studies 
with multiple subjects, the between-subject variability in nicotinergic drug induced effects were 
not addressed clearly. For instance, Yang et al. (2013) presented individual PHA-543613 dose-
dependent behavioral performance in DMTS task in two monkeys who had similar profiles. 
However, a total of 11 subjects including male, female, aged and young monkeys were included 
in the study. While the authors mention generally that performance was improved in both younger 
and older monkeys, they do not clearly state which specific aspect of performance was improved 
by other subjects. It is also not clear whether both genders benefited from the drug. A previous 
study with general nicotinic agonist by Buccafusco et al. (1999) suggested that drug-induced 
increase in performance accuracy is different across aged female and male monkeys. They also 
suggested that females may need a higher level of individualized dose selection and higher doses 
of nicotine to achieve the same behavioral effects as males. Between-subject variability in effective 
doses for inducing comparable behavioral improvement have been reported by a number of 
monkey studies who used selective nicotinergic agonists in subjects with comparable gender 
or/and ages (Decker et al., 1997; Gould et al., 2013). Since individualized best doses are selected 
from a series of options, there is a need for repeated testing of the assumed best dose in the same 
subject to ensure reliable behavioral enhancement with that particular dose (Buccafusco et al., 
1995). However, dose repetitions are usually reported up to 2 or 3 times for each individual (see 
for example (Gould et al., 2013) and  (Buccafusco et al., 1995)).  
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Each drug dose in this thesis has been repeated at least 6 times across different days of the 
week in a blinded experiment. Therefore, while current findings may be limited to one subject 
only, they provide reliable results in specific aspects of attention and learning. 
4.3 Future Directions 
Do differential behavioral effects also correspond to differential neural activities in brain areas 
important for cognitive flexibility and attention control when the monkey is administered with 
these two drugs? To address this question, another future step can be to conduct extracellular 
recording from multiple brain areas simultaneously as a subject is performing the task. As 
discussed in the introduction of this thesis, different brain areas are involved in reversal learning 
and attentional processes. Flexible goal-directed behavior is dependent on neuronal circuits in the 
prefrontal and anterior cingulate cortex (PFC/ACC) (Rothe, Quilodran, Sallet, & Procyk, 2011). 
Additionally, neural activities in cortico-striatal pathway have been shown to play important roles 
in memory and goal-directed learning (Asaad & Eskandar, 2011). The caudate nucleus, located in 
dorsal striatum, receives input from both ACC and PFC and disruptions in the connections between 
these areas are involved in neuropsychiatric disorders such as obsessive compulsive disorder 
(Tekin & Cummings, 2002).  
 Previous studies suggest that neuronal circuits in PFC/ACC implement rapid learning of 
feature relevance through dynamic neuromodulation of local circuit activities in the PFC (Arnsten 
AFT, Wang MJ, 2012; Noudoost & Moore, 2011). Neural recording can address how dynamic 
cholinergic neuromodulation facilitates rapid learning and flexible attentional feature selection and 
how this system affects PFC/ACC circuitry to support the mechanisms underlying such higher 
attentional processes. 
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 Electrochemical in conjunction with electrophysiological recordings in behaving monkeys 
can enable us to measure the concentration of acetylcholine (or other neurotransmitters) in 
different brain areas during the task to understand where in the brain the functional effects on 
learning and distractibility reduction are brought about. It would also inform us of how cholinergic 
modulation induced by nicotinic sub-receptors affect the neural circuitry underlying cognitive 
flexibility and attentional processes (Vizi & Lendvai, 1999). Electrochemical methods are 
available in rodents and have been used to measure acetylcholine release in the PFC of behaving 
rodents (Parikh et al., 2007). However, advances towards building these methods are still in 
progress (Disney et al., 2015). 
4.4 Conclusion  
 Overall, PHA-543613 and ABT-089 had differential effects on performance accuracy, 
learning rate and distraction filtering respectively. By implementing a complex feature-based 
reversal learning task which allowed for assessment of cognitive flexibility and attentional 
processes, these findings suggest that α7 and α4β2 nicotinergic sub-receptors play distinct roles in 
mediating higher order cognitive functions. The α7 agonist PHA-543613 broadly improved 
learning performance while the α4β2 agonist ABT-089 reduced distractibility and improved 
performance accuracy in trials with the highest attentional demand to filter distraction. The results 
of this thesis also suggested that the agonist-induced pro-cognitive effects were time and dose 
dependent. These findings add new insight about the distinct contributions of the two most 
prominent nicotinic sub-receptors in the mammalian brain to learning and attention in non-human 
primates.  
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Appendix A Training of Monkey K 
Monkey K has been under training with the objective of learning the feature based reversal learning 
task that Monkey H performed for this project. As of now, Monkey K can attend to a stimulus 
under all three different timings; albeit, in comparison to the final task version, there are two 
differences in this regard: 1) The color does not dim; it brightens as a signal of response timing. 2) 
The brightening is tied to motion onset; in other words, the go-cue signal is removed. Additionally, 
there are only eight trial types that Monkey K performs in the current task version (Fig. 26).  These 
changes helped Monkey K to learn the concept of responding to a rewarded stimulus under 
different timings. Eventually, the goal is to add a go-cue signal such as a later step in training. 
Monkey K is also able to perform reversals with the guidance of a colored cue presented at the 
fixation point. Basically, the cue shows him which color is rewarded in each block. With this task 
version, he is capable of reaching a criterion of 80% within 10 trials in a block with a minimum of 
30 and 50 trials. The goal is to phase out the cue so that Monkey K can do reversals with trial and 
error i.e. through receiving feedback from his choices. The stimuli and setup are comparable to 
ones that Monkey H was exposed to in terms of display background, motion speed, radius and 
distance from cue. However, the colors yellow and deep sky blue were chosen for Monkey K due 
to the animal’s preferences. Moreover, as part of training the animal for the cued version of the 
task, a 20-pixel size rhombus (diamond) shaped cue was introduced for fixation point. To maintain 
consistency between the two subjects, the diamond cue will be changed to a 15-pixel size circle 
later in throughout the training. 
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Figure 26 Eight possible conditions presented at the current task for Monkey K. Trials that started 
with motion onset first are non-existent in this version. It should be noted that the stimuli were 
colored as yellow and deep sky blue for Monkey K.  
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Appendix B.1 Expectation Maximization Algorithm 
 
The model is a dynamic approach which estimates subject’s learning as a probability of achieving 
a correct response as a function of each trial in a task with binary responses.  Binary responses of 
the subject (correct or incorrect) are fed as input into the algorithm which in return provides a 
learning curve for each block. This state-space model paradigm consists of smoothing algorithm, 
which takes the perspective of an ideal observer, and filtering expectation maximization 
algorithms, which takes the perspective of the subject. The estimation of both gives a probability 
density for the correct response probability at a given trial. The mode values of this probability 
density were used to generate the learning curve in this thesis. The ideal observer also estimates a 
learning trial as the first trial on which the lower bound of the 95% confidence interval for the 
probability of a rewarded choice or correct answer is higher than obtaining the correct answer by 
chance (i.e. 50%)  and remains above this chance level throughout the block (Fig. 27). 
 
 
 
 
 
 
 
 
  96 
 
 
 
 
   
Figure 27 Probability of a rewarded choice per trial from reversal estimated by EM algorithm. 
The grey squares on top of the performance curve present non-choice errors while the black 
squares present correct choices. The ideal observer has estimated the learning occurring reliably 
above chance level at trial 5. 
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Appendix B.2 Randomization Test Implemented for Evaluation of Hyperbolic-Ration 
Function Fitting  
 A randomization procedure was carried out to test the significance of differences in the parameters 
of interest estimated by the hyperbolic-ratio function between drug and control conditions. The 
randomization procedure followed the steps described by Maris and Oostenveld (2007).  
The difference between the estimated parameters of interest under each treatment were computed. 
Then, one dataset matrix was built out of the two datasets in which drug & control condition labels 
were randomized. A dataset as the same size of each condition was extracted. The function was fit 
to the averaged performance in all trials across all blocks of the newly constructed matrixes and 
afterward the parameters of interest were estimated in a similar way to datasets with the actual 
condition labels. This process was repeated 1500 times resulting in 1500 number of parameter 
values for each of the two matrix types whose experimental labels were shuffled. The distribution 
of root of mean square error (RSME) of all estimated parameters was constructed and any 
estimation that had RSME above 90% percentile of this distribution was excluded. The difference 
between the estimated parameter values were extracted as test statistics and the 97.5% and 2.5% 
percentiles of the null test statistics distribution was computed to conduct a two-tailed test at 0.05 
alpha significance. These two values served as thresholds based on which the significance of the 
observed difference between the parameters of interest was determined. The proportion of values 
within the null distribution larger than the observed test statistics was calculated as the p value of 
this randomization procedure.  
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Appendix B.3 Two Sample Proportions Z-Test 
In this thesis, the null hypothesis in a two sample proportions z-test stated that the difference 
between the proportions was zero. The z score was computed based on the equation below (Zar, 
2010) where p1 is the first proportion value, p2 is the other proportion value. If null hypothesis 
was true, then p1-p2=0.  P is the proportion of learned blocks calculated by pooling data from both 
control and drug conditions as shown by the following equation: 
 
           
The null hypothesis was rejected if the computed z score at 0.05 alpha level in a two-tailed test 
was above 1.96.  The p value was computed using “Table B.2: Proportions of the normal curve 
(one-tail)” from Zar (2010) by multiplying the value found in the table by 2 (since the test was two 
tailed).  
 
 
  
